PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION APPROACHES IN B-CELL LYMPHOMA by Yang, Qingshan
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
5-2013
PIM KINASE INHIBITION: SINGLE AGENT
AND COMBINATION APPROACHES IN B-
CELL LYMPHOMA
Qingshan Yang
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Yang, Qingshan, "PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION APPROACHES IN B-CELL
LYMPHOMA" (2013). UT GSBS Dissertations and Theses (Open Access). Paper 347.
PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION 
APPROACHES IN B-CELL LYMPHOMA 
by 
Qingshan Yang, B.A. 
 
Approved: 
 
_____________________ 
Varsha Gandhi, Ph.D.  
Advisor 
_____________________ 
Hesham Amin, M.D. 
_____________________ 
Jan Burger, M.D. 
_____________________ 
Joya Chandra, Ph.D. 
_____________________ 
Peng Huang, M.D., Ph.D.  
 
 
 
 
Approved:  
 
_________________________________________                                                                     
Dean, The University of Texas  
Graduate School of Biomedical Sciences at Houston 
PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION 
APPROACHES IN B-CELL LYMPHOMA 
A
DISSERTATION  
Presented to the Faculty of  
The University of Texas
Health Science Center at Houston 
and
The University of Texas
MD Anderson Cancer Center 
Graduate School of Biomedical Sciences at Houston 
in Partial Fulfillment  
of the Requirements 
for the Degree of 
DOCTOR OF PHILOSOPHY 
by 
Qingshan Yang, B.A. 
Houston, Texas 
May, 2013?
iii 
 
Copyright 
© 2013 Qingshan Yang, B.A. All rights reserved. 
  
iv 
 
Dedication 
 
 
 
 
 
 
 
 
To my loving and supportive parents, grandparents, and uncle David.  
Your passion in science has inspired me and guided me to where I am today.  
 
  
v 
 
Acknowledgement 
 
I would like to extend my deepest gratitude towards my Ph.D. advisor, Dr. Varsha Gandhi. 
Your support teaching and mentorship on my academia career development endeavors has been the 
most invaluable experience of my graduate training; your dedication to science and education has 
made you my role model and life-time mentor. Without your generous support, I could not have 
reached the finish line in such efficiency! 
I would also like to express my biggest thank you to my Ph.D. mentor and good friend, Dr. 
Lisa Chen. You have taught me much more than laboratory techniques and scientific writing. Also 
thank you for holding my hand through each milestone during my training, I could not have done it 
without you! 
Special thank you to all of my committee members, Drs. Hesham Amin, Jan Burger, Joya 
Chandra and Peng Huang! Thank you for providing helpful advises on my thesis projects through the 
past 3 years, and helping me to become a better scientist.   
Additional thank you to Bill, for your support and help along the way, and thank you for all 
the helpful suggestions from lab meetings on my projects, and the very supportive recommendation 
letters as well as the thoughtful notes you passed to me on various occasions.  
Many thanks to… 
My current lab mates, Shadia Zaman and Viral Patel, Fabiola Gomez, Yingjun Jiang and 
Prexy Shah, for providing good company and very helpful tips and suggestions during my thesis 
writing, and throughout my Ph.D. training.  
Every member of the Cellular and Molecular Pharmacology group! Thank you for providing 
valuable assistance throughout my Ph.D. training here, for all the protocols, reagents, trouble-
shootings and also for all the moral supports! I am so fortunate to be in this group!  
vi 
 
PIM KINASE INHIBITION: SINGLE AGENT AND COMBINATION 
APPROACHES IN B-CELL LYMPHOMA 
Publication no._________ 
Qingshan Yang, B.A. 
Advisor: Varsha Gandhi, Ph.D. 
Proviral integration site for Moloney murine leukemia virus (Pim) kinases are Ser/Thr/Tyr 
kinases. They modulate B-cell development but become oncoproteins and promote cancer 
development once overexpressed. Containing three isoforms, Pim-1, -2 and -3 are known to 
phosphorylate various substrates that regulate transcription, translation, cell cycle, and survival 
pathways in both hematological and solid tumors.   
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma. Elevated Pim kinase levels 
are common in MCL, and it negatively correlates with patient outcome. SGI-1776 is a small 
molecule inhibitor selective for Pim-1/-3. We hypothesize that SGI-1776 treatment in MCL will 
inhibit Pim kinase function, and inhibition of downstream substrates phosphorylation will disrupt 
transcriptional, translational, and cell cycle processes while promoting apoptosis.  
SGI-1776 treatment induced moderate to high levels of apoptosis in four MCL cell lines 
(JeKo-1, Mino, SP-53 and Granta-519) and peripheral blood mononuclear cells (PBMCs) from MCL 
patients. Phosphorylation of transcription and translation regulators, c-Myc and 4E-BP1 declined in 
both model systems. Additionally, levels of short-lived Mcl-1 mRNA and protein also decreased and 
correlated with decline of global RNA synthesis. Collectively, our investigations highlight Pim 
kinases as viable drug targets in MCL and emphasize their roles in transcriptional and translational 
regulation.  
vii 
 
We further investigated a combination strategy using SGI-1776 with bendamustine, an FDA-
approved DNA-damaging alkylating agent for treating non-Hodgkin’s lymphoma. We hypothesized 
this combination will enhance SGI-1776-induced transcription and translation inhibition, while 
promoting bendamustine-triggered DNA damage and inducing additive to synergistic cytotoxicity in 
B-cell lymphoma.  
Bendamustine alone resulted in moderate levels of apoptosis induction in MCL cell lines 
(JeKo-1 and Mino), and in MCL and splenic marginal zone lymphoma (a type of B-cell lymphoma) 
primary cells. An additive effect in cell killing was observed when combined with SGI-1776. 
Expectedly, SGI-1776 effectively decreased global RNA and protein synthesis levels, while 
bendamustine significantly inhibited DNA synthesis and generated DNA damage response. In 
combination, intensified inhibitory effects in DNA, RNA and protein syntheses were observed. 
Together, these data suggested feasibility of using Pim kinase inhibitor in combination with 
chemotherapeutic agents such as bendamustine in B-cell lymphoma, and provided foundation of 
their mechanism of actions in lymphoma cells.   
 
  
viii 
 
Table of Contents 
 
Copyright ............................................................................................................................................. iii 
Dedication ............................................................................................................................................ iv 
Acknowledgement ................................................................................................................................ v 
Abstract ................................................................................................................................................ vi 
Table of Contents ............................................................................................................................... viii 
List of Figures .................................................................................................................................... xiii 
List of Tables ..................................................................................................................................... xvi 
Abbreviations .................................................................................................................................... xvii 
CHAPTER 1. Introduction 
Pim kinases and their role in physiology and tumorigenesis ................................................................ 1 
Pim kinase oncogenes .............................................................................................................. 1 
Pim and Myc cooperation ........................................................................................................ 3 
Pim kinase and early response genes ....................................................................................... 4 
Pim kinase in B-cell development and hematological malignancies ....................................... 4 
B-cell lymphoma disease characteristics ............................................................................................... 5 
B-cell lymphoma overview ...................................................................................................... 5 
Mantle cell lymphoma and its molecular pathogenesis ........................................................... 7 
Pim kinases overexpression and lymphomagenesis in B-cell lymphoma ................................ 8 
Pim kinases substrates and functions .................................................................................................... 8 
Pim kinases and transcription regulation ................................................................................. 9 
Pim kinases and translation regulation ..................................................................................... 9 
Pim kinases and cell survival regulation ................................................................................ 12 
Pim kinases and cell cycle regulation .................................................................................... 12 
Pim kinase inhibitor ............................................................................................................................ 13 
Pim kinase small molecule inhibitor‒SGI-1776 .................................................................... 13 
Other Pim kinase inhibitors .................................................................................................... 14 
Bendamustine ...................................................................................................................................... 14 
ix 
 
CHAPTER 2. Materials and Methods 
Cell lines ............................................................................................................................................. 18 
Primary cells from MCL and other B-cell lymphoma patients ........................................................... 18 
Drugs ................................................................................................................................................... 19 
Apoptosis assays ................................................................................................................................. 19 
Cell cycle assays ................................................................................................................................. 19 
Immunostaining of γ-H2AX ............................................................................................................... 20 
Immunohistochemistry ........................................................................................................................ 20 
Macromolecule synthesis assays ......................................................................................................... 21 
Gene expression assays ....................................................................................................................... 21 
Protein expression assays with immunoblots ...................................................................................... 22 
siRNA transfection .............................................................................................................................. 22 
Data analysis ....................................................................................................................................... 24 
CHAPTER 3. SGI-1776 single agent treatment in MCL 
Aim 1. Analyze the biological consequences of SGI-1776 in MCL cells.  
1.1. Expression of Pim kinases in MCL cell lines and primary tissue samples .................................. 25 
Expression of Pim kinases in MCL cell lines.  ...................................................................... 25 
Expression of Pim kinases in MCL primary tissue samples.  ................................................ 27 
1.2. Detection of SGI-1776 induced dose- and time-dependent apoptosis in MCL cell lines ............ 27 
Induction of dose-dependent apoptosis by SGI-1776  ........................................................... 27 
Induction of time-dependent apoptosis by SGI-1776 ............................................................ 40 
Aim 2. Identify the biological function of Pim kinases in their signaling pathways and 
biomarkers impacted by SGI-1776 in MCL cells.  
2.1. Effect of SGI-1776 on Pim kinase phosphorylation targets in MCL cell lines ............................ 40 
Effect of SGI-1776 on transcription regulator c-Myc ............................................................. 43 
Effect of SGI-1776 on transcription regulator Histone H3  .................................................... 43 
Effect of SGI-1776 on translation regulator 4E-BP1  ............................................................. 43 
Effect of SGI-1776 on cell survival regulator Bad ................................................................. 50 
2.2 Effect of SGI-1776 on RNA synthesis and MCL1 gene expression levels in MCL cell line ........ 50 
x 
 
Effect of SGI-1776 on global RNA synthesis  ....................................................................... 50 
Effect of SGI-1776 on MCL1 gene expression levels  ........................................................... 55 
2.3 Effect of SGI-1776 on anti-apoptotic protein expression levels in MCL cell lines. ..................... 58 
Effect of SGI-1776 on Mcl-1 protein expression levels  ....................................................... 58 
Effect of SGI-1776 on other anti-apoptotic proteins  ............................................................. 61 
2.4 Effect of SGI-1776 on cell cycle profile and cell cycle regulators in MCL cell lines .................. 61 
Effect of SGI-1776 on cell cycle profiles  ............................................................................. 61 
Effect of SGI-1776 on cdc25C phosphorylation  ................................................................... 66 
Effect of SGI-1776 on cyclin D1 levels  ................................................................................ 66 
2.5 Effect of PIM1, PIM2, PIM1/2 siRNA in MCL cell lines ............................................................ 70 
Effect of PIM1, 2, PIM1/2 siRNA treatment on PIM1, 2 and MCL1 mRNA levels  ............ 70 
Effect of PIM1, 2, PIM1/2 siRNA on Mcl-1 protein levels in JeKo-1 .................................. 75 
Effect of PIM1, 2, PIM1/2 siRNA on Mcl-1 protein levels in Mino ..................................... 78 
Effect of PIM1, 2, PIM1/2 siRNA on Pim kinase phosphorylation targets in JeKo-1 ........... 78 
Effect of PIM1, 2, PIM1/2 siRNA on Pim kinase phosphorylation targets in Mino ............. 78 
2.6 Effect of SGI-1776 in MCL primary cells .................................................................................... 85 
Effect of SGI-1776 on Pim kinase phosphorylation targets in MCL primary cells ............... 85 
Effect of SGI-1776 on Mcl-1 and cyclin D1 levels in MCL primary cells ............................ 85 
Effect of SGI-1776 on Pim kinase phosphorylation targets in normal PBMCs ..................... 89 
Effect of SGI-1776 on Mcl-1 and cyclin D1 levels in normal PBMCs ................................. 94 
Effect of SGI-1776 on MCL1 mRNA levels in MCL primary cells ...................................... 94 
Effect of SGI-1776 on MCL1 mRNA levels in normal PBMCs ............................................ 94 
2.7 Relationships among events of transcription, translation and cell death in MCL cell lines........ 101 
Relationship between global transcription inhibition and cell death  .................................. 101 
Relationship between reduction of c-Myc (Ser62) phosphorylation  
and inhibition of global transcription  .................................................................................. 101 
Relationship between reduction of c-Myc (Ser62) phosphorylation  
and decrease of MCL1 mRNA levels ................................................................................... 104 
Relationship between reduction of 4E-BP1 (Thr37/46) phosphorylation  
and cell death ....................................................................................................................... 104 
Relationship between reduction of 4E-BP1 (Thr37/46) phosphorylation  
and decrease of Mcl-1 protein levels ................................................................................... 107 
xi 
 
CHAPTER 4. Combination of bendamustine and SGI-1776 in B-cell lymphoma 
Aim 3. Explore the combination strategy of bendamustine and SGI-1776 to identify  
primary mechanism of actions of cytotoxicity induction in B-cell lymphoma.  
3.1 Effect on apoptosis induction by bendamustine and SGI-1776 combination treatment  
      in B-cell lymphoma cells ............................................................................................................ 109 
Effect on apoptosis induction by bendamustine and SGI-1776 combination treatment  
in MCL cell lines .................................................................................................................. 109 
Effect on apoptosis induction by bendamustine and SGI-1776 combination treatment  
in B-cell lymphoma primary cells ........................................................................................ 111 
3.2 Effect on DNA synthesis inhibition by bendamustine and SGI-1776 combination  
      in JeKo-1 ..................................................................................................................................... 118 
3.3 Effect on RNA synthesis inhibition by bendamustine and SGI-1776 combination  
      in JeKo-1 and B-cell lymphoma primary cells ............................................................................ 120 
3.4 Effect on protein synthesis inhibition by bendamustine and SGI-1776 combination  
      in JeKo-1 and B-cell lymphoma primary cells  ........................................................................... 124 
3.5 Effect on DNA damage marker γ-H2AX by bendamustine and SGI-1776 combination  
      in JeKo-1  .................................................................................................................................... 126 
CHAPTER 5. Discussion and Conclusion 
Summary ........................................................................................................................................... 132 
SGI-1776 primary mechanism of actions in MCL ............................................................................ 133 
MCL cell line as primary model of study ............................................................................ 133 
Primary patient samples as important predictors of drugs’ clinical outcomes ..................... 139 
Targeting c-Myc-driven transcription .................................................................................. 139 
Targeting cap-dependent translation .................................................................................... 142 
Targeting cell survival machinery ........................................................................................ 142 
Targeting cell cycle .............................................................................................................. 146 
Pim kinase redundant pathways ........................................................................................... 147 
SGI-1776 cytotoxicity and second generation Pim kinase inhibitors .................................. 148 
Combination of bendamustine with SGI-1776 in B-cell lymphoma ................................................. 150 
Targeting DNA synthesis ..................................................................................................... 150 
Targeting RNA synthesis ..................................................................................................... 151 
Targeting protein synthesis .................................................................................................. 152 
xii 
 
Additive to synergistic effect in cell killing ......................................................................... 153 
Other combination methods involving Pim kinase inhibitors .............................................. 153 
Advantage of using Pim kinase inhibitor to prevent drug resistance ................................... 155 
Conclusion and future direction ........................................................................................................ 155 
References ......................................................................................................................................... 158 
Vita .................................................................................................................................................... 172 
 
 
  
xiii 
 
List of Figures 
 
Figure 1. Pim kinase genes, transcripts and proteins  ........................................................................... 2 
Figure 2. Pim kinase downstream phosphorylation substrates  
                and Pim kinase-regulating pathways. .................................................................................. 11 
Figure 3. Chemical structure of Pim kinase inhibitor, SGI-1776 ........................................................ 15 
Figure 4. Chemical structure of alkylating agent, bendamustine hydrochloride ................................. 17 
Figure 5. Expression of all three Pim kinases in JeKo-1 and Mino cell lines ..................................... 26 
Figure 6. Expression of three Pim kinases in MCL primary tissue samples ....................................... 28 
Figure 7. Increase in apoptosis by SGI-1776 treatment in JeKo-1 cells measured  
                by annexin V/PI assay ......................................................................................................... 31 
Figure 8. Increase in apoptosis by SGI-1776 treatment in Mino cells measured  
                  by annexin V/PI assay  ...................................................................................................... 33 
Figure 9. Increase in apoptosis by SGI-1776 treatment in Granta 519 cells measured  
                  by annexin V/PI assay ....................................................................................................... 35 
Figure 10. Increase in apoptosis by SGI-1776 treatment in SP-53 cells measured  
                  by annexin V/PI assay ....................................................................................................... 37 
Figure 11. Induction of dose-dependent apoptosis by SGI-1776in MCL cell lines ............................ 39 
Figure 12. Induction of time-dependent apoptosis by SGI-1776in MCL cell lines ............................ 42 
Figure 13. Effect of SGI-1776 on Pim kinase target, c-Myc, in MCL cell lines ................................ 45 
Figure 14. Effect of SGI-1776 on Pim kinase target, Histone H3, in MCL cell lines ......................... 47 
Figure 15. Effect of SGI-1776 on Pim kinase target, 4E-BP1, in MCL cell lines .............................. 49 
Figure 16. Effect of SGI-1776 on Pim kinase target, Bad, in MCL cell lines .................................... 52 
Figure 17. Inhibition of global RNA synthesis by SGI-1776 in MCL cell lines ................................. 54 
Figure 18. Reduction of MCL1 mRNA expression levels by SGI-1776 in MCL cell lines ................ 57 
Figure 19. Dose-dependent reduction of Mcl-1 protein expression levels  
                  by SGI-1776 in MCL cell lines  ........................................................................................ 60 
Figure 20. Time-dependent reduction of Mcl-1 protein expression levels  
                  by SGI-1776 in MCL cell lines  ........................................................................................ 63 
Figure 21. Effect on other Bcl-2 family proteins and XIAP by SGI-1776 in MCL cell lines............. 65 
xiv 
 
Figure 22. Cell line-specific differential effect on cell cycle treatment  
                  by SGI-1776 in MCL cell lines  ........................................................................................ 68 
Figure 23. Cell line-specific effect on cdc25C phosphorylation by SGI-1776 in MCL cell lines ...... 69 
Figure 24. Cell line-specific effect on cyclin D1 expression levels  
                  by SGI-1776 in MCL cell lines ......................................................................................... 72 
Figure 25. Effect on PIM1, PIM2, MCL1 mRNA expression levels  
                  by PIM1, PIM2, PIM1/2 siRNA treatments in MCL cell lines ......................................... 74 
Figure 26. Effect on Mcl-1 protein expression levels  
                  by PIM1, PIM2, PIM1/2 siRNA treatments in JeKo-1 cells  ............................................ 77 
Figure 27. Effect on Mcl-1 protein expression levels  
                  by PIM1, PIM2, PIM1/2 siRNA treatments in Mino cells  ............................................... 80 
Figure 28. Effect on Pim kinase phosphorylation targets  
                  by PIM1, PIM2, PIM1/2 siRNA treatments in JeKo-1 cells  ............................................ 82 
Figure 29. Effect on Pim kinase phosphorylation targets  
                  by PIM1, PIM2, PIM1/2 siRNA treatments in Mino cells  ............................................... 84 
Figure 30. Dose-dependent reduction of Pim kinase phosphorylation targets 
                  by SGI-1776 treatment in MCL primary cells .................................................................. 88 
Figure 31. Dose-dependent reduction of Mcl-1 and cyclin D1 protein expression levels 
                  by SGI-1776 treatment in MCL primary cells  ................................................................. 91 
Figure 32. Dose-dependent reduction of Pim kinase phosphorylation targets 
                  by SGI-1776 treatment in normal PBMCs  ....................................................................... 93 
Figure 33. Dose-dependent reduction of Mcl-1 and cyclin D1 protein expression levels 
                  by SGI-1776 treatment in normal PBMCs  ....................................................................... 96 
Figure 34. Effect on MCL1 mRNA expression levels  
                  by SGI-1776 treatment in MCL primary cells. ................................................................. 98 
Figure 35. Effect on MCL1 mRNA expression levels  
                  by SGI-1776 treatment in normal PBMCs  ..................................................................... 100 
Figure 36. Strong correlation between global RNA synthesis inhibition and cell death lead  
                  by SGI-1776 treatment in MCL cell lines. ...................................................................... 102 
Figure 37. Strong correlation between decrease of c-Myc phosphorylation and RNA synthesis 
                  inhibition by SGI-1776 treatment in MCL cell lines. ..................................................... 103 
Figure 38. Strong correlation between decrease of c-Myc phosphorylation and decrease of MCL1 
                  mRNA levels by SGI-1776 treatment in MCL cell lines. ............................................... 105 
xv 
 
Figure 39. Strong correlation between decrease of 4E-BP1 phosphorylation and cell death 
                  by SGI-1776 treatment in MCL cell lines. ...................................................................... 106 
Figure 40. Strong correlation between decrease of 4E-BP1 phosphorylation and decrease  
                  of Mcl-1 protein levels by SGI-1776 treatment in MCL cell lines. ................................ 108 
Figure 41. Rationale for combination strategy of bendamustine with SGI-1776 in MCL ................ 110 
Figure 42. Cell death induced by bendamustine and SGI-1776 combination treatment  
                  in MCL cell lines ............................................................................................................. 113 
Figure 43. Cell death induced by bendamustine and SGI-1776 combination treatment  
                  in B-cell lymphoma primary cells ................................................................................... 117 
Figure 44. Effect of bendamustine and SGI-1776 combination treatment on DNA synthesis  
                  inhibition by in JeKo-1 cells. .......................................................................................... 119 
Figure 45. Effect of bendamustine and SGI-1776 combination treatment on RNA synthesis  
                  inhibition in JeKo-1 cells. ............................................................................................... 121 
Figure 46. Effect of bendamustine and SGI-1776 combination treatment on RNA synthesis  
                  inhibition in B-cell lymphoma primary cells. ................................................................. 123 
Figure 47. Effect of bendamustine and SGI-1776 combination treatment on protein synthesis  
                  inhibition in JeKo-1 cells. ............................................................................................... 125 
Figure 48. Effect of bendamustine and SGI-1776 combination treatment on protein synthesis  
                  inhibition in B-cell lymphoma primary samples. ............................................................ 128 
Figure 49. Effect of SGI-1776 treatment on bendamustine-induced γ-H2AX expression  
                  in JeKo-1 cells  ................................................................................................................ 131 
Figure 50. An overall model to summarize main findings. ..............................................................  134 
Figure 51. SGI-1776 treatment decreases transcription by disrupting phosphorylation of  
                  c-Myc and Histone H3. ................................................................................................... 141 
Figure 52. SGI-1776 treatment decreases translation by disrupting phosphorylation of 4E-BP1. ... 143 
Figure 53. SGI-1776 treatment disrupts phosphorylation of Bad which contribute to cell death. .... 144 
 
  
xvi 
 
List of Tables 
 
Table 1. Primary antibodies used in immunoblot analyses and their sources ..................................... 23 
Table 2. Incidence of Pim kinase expression in immunohistochemically stained  
              MCL primary tissue samples ................................................................................................ 29 
Table 3. MCL patient characteristics .................................................................................................. 86 
Table 4. Fractional analysis of combination of SGI-1776 with bendamustine  
              in B-cell lymphoma ............................................................................................................. 114 
Table 5. B-cell lymphoma patient characteristics ............................................................................. 115 
Table 6. MCL cell lines growth condition and characteristics .......................................................... 135 
Table 7. Surface CD markers of MCL cell lines ............................................................................... 136 
Table 8. Oncogene, tumor suppressor and cell cycle marker expressions in MCL cell lines ........... 137 
Table 9. Bcl-2 family protein expressions in MCL cell lines ........................................................... 138 
 
 
  
xvii 
 
List of Abbreviations 
4E-BP1   eukaryotic translation initiation factor 4E-binding protein 1 
ABCB1  multidrug resistant protein 1 
ABCG2  breast cancer resistance protein  
AIF   apoptosis-inducing factor 
Akt   protein kinase B  
AML   acute myeloid leukemia 
ATM   ataxia telangiectasia mutated 
ATP   adenosine 5’-triphosphate 
Bad   Bcl-2‒associeated death promoter 
BAFF   B-cell activating factor 
Bcl-2   B-cell lymphoma 2 
Bcl-XL   B-cell lymphoma-extra large 
BCR   B-cell receptor 
BLyS   B lymphocyte stimulator 
BSA   bovine serum albumin 
CD   cluster of differentiation 
CDC25A/C  cell division cycle 25A/C 
CDK   cyclin-dependent kinase 
CDKN1B (p27)  cyclin-dependent kinase inhibitor 1B 
CHOP/R-CHOP cyclophosphamide, doxorubicin, vincristine, prednisone ± rituximab 
CLL   chronic lymphocytic leukemia 
c-Myc   myelocytomatosis viral oncogen homolog 
DHAP   dexamethasone, cytarabine and cisplatin 
DLBCL  diffused large B-cell lymphoma 
xviii 
 
DMSO   dimethyl sulfoxide 
DPM   disintegration per minute 
4E-BP1   eukaryotic translation initiation factor 4E-binding protein 1 
eIF4   eukaryotic initiation factor 4 
FBS   fetal bovine serum 
FL   follicular lymphoma 
Flt3   Fms-like tyrosine kinase 3 
GC   germinal center 
H2AX   Histone 2A variant X 
HSP   heat shock protein 
IC50   half-maximal inhibitory concentration 
Ig   immunoglobulin 
JAK   Janus kinase 
LDH   lactic acid dehydrogenase 
MCL   mantle cell lymphoma 
Mcl-1   induced myeloid leukemia cell differentiation protein 
MDM2   mouse double minute 2 homolog 
MM   multiple myeloma 
mRNA   messenger ribonucleic acid 
mTOR   mammalian target of rapamycin 
NF-ĸB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NHL   non-Hodgkin’s lymphoma 
NOXA   Phorbol-12-myristate-13-acetate-induced protein 1 
PARP   poly (ADP-ribose) polymerase 
PBMC   peripheral blood mononuclear cells  
PBS   phosphate-buffered saline  
xix 
 
PI3K   phosphatidylinositide 3-kinases  
RB1   retinoblastoma protein 
RCC   renal cell carcinoma 
RICE   ifosfamide, carboplatin and etoposide with rituximab  
RPPA   reverse-phase protein microarray 
RUNX   runt-related transcription factors 
p21   cyclin-dependent kinase inhibitor 1 
p27   cyclin-dependent kinase inhibitor 1B 
Pim   proviral integration site for Moloney murine leukemia virus 
rpm   rotations per minute  
RT-PCR  reverse transcription polymerase chain reaction 
SEM   standard error of the mean 
SHM   somatic hypermutation 
siRNA   small interfering ribonucleic acid  
SMZL   small marginal zone lymphoma 
SOCS   signaling transducer and suppressor of cytokine signaling 
SOX11   sry-related high-mobility-group box 11 
STAT   signal transducer and activator of transcription 
TrkA   transforming tyrosine kinase protein 
 
 
  
1 
 
CHAPTER 1. Introduction 
I. Pim kinases and their role in physiology and tumorigenesis  
Pim kinase oncogenes  
Proviral integration site for Moloney murine leukemia virus (Pim) kinases are Ser/Thr/Tyr 
kinases (Selten 1986; Telerman 1988; Hoover 1991) and Pim-1 (the founding member of the Pim 
kinase family) was first discovered in 1980s (Selten 1986; Telerman 1988). Oncogenic feature of 
PIM1 gene was revealed as it contains a small region of murine chromosome, to which murine 
leukemia virus (MuLV) frequently integrate itself. This integration site is associated with 
transcription activation that leads to activation of PIM1 gene, which ultimately induced development 
of T-cell lymphoma with high incidence in the MuLV-infected murine models (Cuypers 1984).   
To date, there are three identified isoforms, Pim-1, -2 and -3, located at different 
chromosomes in the mouse and human genomes and they share structural and functional similarities 
(Figure 1). Amino acid sequence of PIM2 and PIM3 share 61% and 71% similarity of PIM1 
sequence, respectively (Mikkers 2004). Pim kinases, especially Pim-1 and Pim-2, are expressed in 
hematological systems, whereas Pim-1 and Pim-3 are expressed in other organs such as testis, kidney 
and brain (Konietzko 1999; Mikkers 2004). Pim-1 was first reported as a cytoplasmic kinase, 
however, recent studies has shown that once truncated at C-terminus, Pim-1 can become nuclear and 
play a role in chemoresistance induction (Telerman 1988; Walpen 2012). Pim-2 is known to be both 
nuclear and cytoplasmic (Gomez-Abad 2011; Levy 2012), and it works in cytoplasm to enhance 
functions of other transcription factors such as NF-ĸB (Hammerman 2004; Chen 2005). In colon 
cancer cells, it appears that Pim-3 expression is sub-nuclear or cytoplasmic (Popivanova 2007). 
These Pim kinases functionally compensate one another as confirmed by Pim-1/-2 double knockout 
or Pim-1/-2/-3 triple knockout studies in mice (Mikkers 2004; An 2013).  
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The transcripts of all three Pim kinases are encoded by six exons, along with large 
untranslated regions (UTRs) at 5’ and 3’ ends as depicted in the figure. At the 5’ end of these 
transcripts, there are G/C-rich regions (blue lariats) and 5 copies of AUUUA destabilizing motifs 
(orange circles) making them labile and short-lived mRNAs (Mikkers 2004). Translation of Pim-1 
and Pim-2 proteins are initiated at alternative sites (light blue boxes and solid or dashed arrows), 
generating protein isoforms of different molecular weights. However, the kinase domains are highly 
-conserved among all three Pim kinases (white boxes) and their functional activity are retained 
(Mikkers 2004). Pim kinases are constitutively active as they do not require post-translational 
modification to activate the proteins (Qian 2005). However, there are reported phosphorylation sites 
mediated by tyrosine kinase ETK at Y218 or autophosphorylation at S8, and the former is known to 
enhance Pim kinase activity (Kim 2004; Bullock 2005). Pim kinase stability is regulated by 
ubiquitylation and proteasome degradation processes, as well as microRNAs (Thomas 2012) (Linn 
2012). 
Pim and Myc cooperation  
 It was reported that activation of c-Myc proto-oncogene was observed when MuLV-proviral 
DNA insertion leads to B-cell lymphoma development, which suggested a potential collaboration of 
Pim kinase and c-Myc in the process tumorigenesis (Selten 1986). This phenomenon was later 
confirmed by transgenic mice study of co-expressing the two proto-oncogenes (Eµ-Pim1;Eµ-Myc), 
which lead to prenatal development of lymphomas (Verbeek 1991). Interestingly, Eµ-Myc transgenic 
mice deficient for Pim-1showed delayed development of lymphoma, indicating the dependency of 
Myc-driven tumorigenesis on Pim kinase expression levels (Verbeek 1991). It was later confirmed 
that such synergism in tumorigenesis was also observed between Pim-2 and c-Myc, further 
suggesting Pim-2 as proto-oncogene and indicating its role in lymphomagenesis (Allen 1997). In 
addition, Pim-3 can substitute for Pim-1/-2 condition as it becomes activated by proviral insertion in 
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Pim-1/-2-deficient state, which also indicates the importance of Pim/Myc axis in lymphomagenesis 
(Mikkers 2004).  
Pim kinase and early response genes 
Pim kinases genes are early response genes (Polotskaya 1993). The 5’ UTR site of Pim 
kinase transcripts contain a long G/C rich region, render them unstable transcripts and hence require 
cap-dependent translation (Domen 1987; Hoover 1997). There has been evidence that Pim-1 protein 
expression is dramatically increased after 5’UTR is depleted or translation initiation factor E4 (eIF4E) 
is overexpressed (Hoover 1997). This event triggers the assembly process of eIF4E complex and 
recruitment of 40S ribosomal subunit to bind to the “capped” 5’-m7G translation initiation site of 
PIM1 mRNA (Hoover 1997; Richter 2005). In addition, the PIM1 3’ UTR also binds to eIF4E 
specifically, and induces nuclear export of the PIM1 transcript which enhances translation activity 
(Culjkovic 2006). Notably, in absence of eIF4E, this process did not occur, further suggesting that 
Pim kinase translation is cap-dependent (Hoover 1997).  
Pim kinase in B-cell development and hematological malignancies 
Pim kinases are known to be involved in production, proliferation, and survival of normal 
blood cells. For instance, in hematological system, Pim-1 and Pim-2 proteins expression can be 
induced by multiple cytokines, mitogens and growth factors, suggesting their role in mediating signal 
transduction pathways (Dautry 1988; Mikkers 2004). During fetal hematopoiesis, Pim-1 is expressed 
at high levels in liver and spleen, whereas in adults, it is only detected in circulating granulocytes 
(Amson 1989).  
However, Pim kinases are dispensable in nature, as Pim-1/-2/-3 triple knockout mouse 
remain viable and fertile (Mikkers 2004). However, these animals were smaller in size at birth and 
throughout their life span (Mikkers 2004). Meanwhile, they show deficiency in hematological 
system such as anemia, erythrocyte microcytosis, reduced peripheral T- and B-cell numbers, and 
5 
 
impaired responses of hematopoietic cell population to a distinct range of growth factors such as IL-
2, IL-3 and IL-7 (Mikkers 2004; An 2013), which are all evidence for the importance of Pim kinases’ 
physiological function during normal hematological development.  
In contrast to normal hematopoiesis, Pim kinases are overexpressed in hematological 
malignancies and become oncogenic in nature as demonstrated by several reports. First, Pim kinases 
gene expression is regulated by signal transduction pathways initiated by growth factors and 
cytokines as mentioned above, most of which transduce their primary signal through Janus kinase/ 
signal transducer and activator of transcription (JAK/STAT) pathway, which are also oncogenic in 
nature (Mikkers 2004). Pim kinase is regulated by this pathway and also feeds back into it, and 
promotes G1-to-S cell cycle transition and prevent cell death (Shirogane 1999; Peltola 2004). Second, 
Pim kinases synergize with c-Myc, an important oncogenic transcription regulator that is also 
overexpressed in hematological malignancies and together they enhance transcription processes 
(Zippo 2007). Third, Pim kinases directly phosphorylate translation regulator eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) that enhances translation (Fox 2003; Chen 2005; 
Tamburini 2009). Fourth, Pim kinases, especially Pim-1 and Pim-2, are known to regulate a variety 
of phosphorylation targets in cell death, cell cycle, and inflammation pathways, along with other 
transcription and translation regulators in both hematological and solid tumors (Brault L. 2010; Chen 
2010). All of the above evidence suggests that Pim kinases have multitude of functions in tumor 
development and progression.  
II. B-cell lymphoma disease characteristics   
B-cell lymphoma overview 
Hematological malignancies are composed of lymphoma, leukemia, myeloma and 
myelodysplastic syndromes (MDS). Lymphoma, categorized into Hodgkin’s and non-Hodgkin’s 
subtypes, is the most common form of these hematological malignancies in the Western world 
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(National Cancer Institute, http://www.cancer.gov/researchandfunding/snapshots/lymphoma). 
Incidence and mortality rate of non-Hodgkin’s lymphoma (NHL) are much higher than that of 
Hodgkin’s lymphoma, while those of B-cell origin take up the vast majority (95%) of NHL cases 
whereas the rest are of T-cell origin (Leukemia and Lymphoma Society, Facts and Statistics 
http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/nhl.
pdf). There are 15 subtypes of B-cell lymphoma under the current lymphoma classification, and 
about 60% of them are aggressive NHL while others are indolent (Leukemia and Lymphoma 
Society).  
B-cell lymphoma is classified based on the point during which their B-cell differentiation 
process is disrupted (Kuppers 1999; Kuppers 2005). In classic NHL, such process is marked by the 
specific structure of B-cell receptor (BCR), the key component that determines the faith of B-cells. 
Properly developed BCR will guide cells towards normal differentiation or apoptosis that yields 
healthy B-cells, whereas abnormally developed BCR leads to uncontrolled proliferation due to 
termination of differentiation which causes B-cell lymphoma development (Greaves 1986; Kuppers 
2005). BCR is composed of two identical copies of heavy and light-chain immunoglobulin (Ig). Only 
B-cell precursors that successfully rearrange Ig heavy- and light-chain to make functional BCR will 
differentiate into mature naïve B-cells, followed by antigen activation during immune responses 
(Kuppers 1999). These antigen-activated B-cells undergo “clonal expansion” in the germinal center 
(GC) of lymph nodes, where they proliferate, differentiate and mutate B-cell antibodies by further 
modifying their Ig gens by somatic hypermutation or class switch ‒both are complicated processes to 
introduce numerous mutations in Ig genes (Kuppers 2005).  
Evidently, most types of B-cell lymphoma derive from GC or post-GC B-cells (Stevenson 
2001). The BCR-guided lymphomagenesis is concluded by a hallmark feature known as “reciprocal 
chromosomal translocation” between one of the Ig loci and a proto-oncogene, placing the proto-
oncogene in control of an active Ig locus promoter region, which leads to deregulated and 
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constitutive expression of this proto-oncogene and turn it into an oncogene (Kuppers 2001). BCL2-
IgH translocation associated with follicular lymphoma and CCDN1-IgVH translocation featured in 
mantle cell lymphoma (MCL) are classic examples of this phenomenon.   
Mantle cell lymphoma and its molecular pathogenesis 
MCL is a form of aggressive B-cell lymphoma that it is very difficult to treat. It constitutes 
about 6% of all NHL cases with highest incidence in elderly Caucasian males. Patients typically 
present disseminated disease upon diagnosis, with leukemic phase in 20-30% of the cases (Perez-
Galan 2011). Although standard frontline chemotherapies are not curative for MCL, they do 
contribute to high remission rates in previously untreated patients. Unfortunately, relapse is common 
within a few years; median survival is 5-7 years (Herrmann 2009). Tumor proliferation is a stronge 
indicator of survival in the clinic (Rosenwald 2003).   
MCL has a genetic hallmark of translocation between 11q13 and 14q23, or t(11;14) 
(q13;q23), a molecular mechanism under overexpression of cyclin D1 in MCL cells. In cases where 
cyclin D1 is not overexpressed, cyclin D2 or D3 instead is detected at high levels (Rosenwald 2003). 
Notably, merely t(11;14) and cyclin D1 overexpression may not be sufficient for full transformation 
of the tumor cells and their aggressive phenotypes (Hinds 1994). A transgenic mice studies where 
CCDN1 gene was linked to an immunoglobulin enhancer suggested that cyclin D1 overexpression 
alone did not lead to lymphomagenesis, but rather, spontaneous development of lymphoma required 
corporation with other oncogenes like MYC (Bodrug 1994; Lovec 1994).  
As with other hematological malignancies, MCL also express a distinct set of CD surface 
markers, CD20+ (high levels), CD5+, CD23+/‒ (mostly negative, but up to 25% of cases are positive) 
and CD11c‒ (Klapper 2011). Newly identified transcription factor Sry-related high-mobility-group 
box 11 (SOX11) has been described as a diagnostic marker which is equally expressed in both cyclin 
D1-positive and -negative MCL cases (Ek 2008; Mozos 2009).  
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The labile and oncogenic cyclin D1 protein forms a complex with other cyclin-dependent 
kinases (CDK) 4 or 6 to enhance cell cycle entry. Consistently, both CDK4 and 6 are commonly 
expressed at high levels in MCL. Aside from cyclin D and CDK family proteins, multiple genetic 
lesions are also detected in MCL, such as Myc, MDM2 oncogene overexpression, and loss of tumor 
suppressor genes retinoblastoma protein (RB1), p53 and ataxia telangiectasia mutated (ATM) (Perez-
Galan 2011). Important cancer-promoting signaling pathways, such as phosphatidylinositide 3-
kinases (PI3K)/ protein kinase B (Akt), nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-ĸB) and JAK/STAT pathways are all upregulated, leading towards accumulation of genetic 
instability, increased transcription, translation and proliferation with less differentiation, all build on 
the augmentation of oncogenicity in MCL (Perez-Galan 2011).   
Pim kinases overexpression and lymphomagenesis in B-cell lymphoma 
 PIM1 and PIM2 mRNA are overexpressed at various incidences in B-cell hematological 
malignancies such as CLL, MCL, diffused large B-cell lymphoma (DLBCL), and follicular 
lymphoma (FL) (Gomez-Abad 2011). Such dysregulated PIM gene expression is not known to be 
caused by gene rearrangement or amplification (Sivertsen 2006), but rather through transcriptional 
regulation, such as JAK/STAT (Shirogane 1999) and NF-ĸB (Hammerman 2004), as well as aberrant 
somatic hypermutation (SHM) observed in NHL such as DLBCL and FL (Pasqualucci 2001; 
Halldorsdottir 2008). In addition, NHL-specific SHM in PIM1 is often accompanies by SHM of 
other oncogenes such as MYC, which further promotes the PIM’s transformation power (Rossi 2006).    
   Notably, Pim kinases are constitutively active due to lack of regulatory domains (Fox 2003; 
Qian 2005). Post-translational regulations are mediated by heat shock proteins (HSP) 70/90, and also 
ubiquitylation processes, which dictates the degradation of these proteins (Shay K.P. 2005). In 
hematological malignancies, Pim kinases exert their lymphomagenesis capacity through 
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phosphorylating downstream targets in transcription and translation regulation, anti-apoptosis 
enhancement as well as cell cycle control processes (Figure 2) (Chen 2010).  
III. Pim kinases substrates and functions 
Pim kinases and transcription regulation 
Myc heterodimerizes with Myc-associated factor X (Max) at E-box sequences, which forms 
a transcription activator complex that is speculated to regulate around 11% of human genes 
(Fernandez 2003). Under growth factor stimulation, Pim kinases bind with Myc/Max dimer complex 
as part of the transcription machinery (Zhang 2008). Pim-1 is also known to phosphorylate c-Myc 
(Ser62), whereas Pim-2 phosphorylates c-Myc (Ser329), both of which contribute to the Pim/Myc 
synergy to stabilize c-Myc protein and to enhance its transcriptional activity. Consistently, knocking 
down of either Pim-1 or Pim-2 dramatically decrease the endogenous level of c-Myc and also its 
oncogenecity (Zhang 2008). It was also demonstrated in human endothelial/epithelial cells that Myc 
helps to recruit Pim-1 to E-box and allows it to phosphorylate Histone H3 (Ser10) to enhance c-Myc 
oncogenecity through upregulated transcription (Zippo 2007).  
In addition, Pim kinases are also known to phosphorylate and activate other transcription 
factors such as Myb, runt-related transcription factors 1 and 3 (RUNX1/3) and signaling transducer 
and suppressor of cytokine signaling 1 and 3 (SOCS1/3), etc. (Chen X.P. 2002; Winn 2003; Wang 
2012).  
Pim kinases and translation regulation 
In translation regulation, Pim-1 and Pim-2 are known to phosphorylate 4E-BP1 (Thr37/46), 
the priming site of this translation inhibitor (Fox 2003). Once 4E-BP1 is primed, it triggers a 
hierarchical hyper-phosphorylation of this protein, causing it to dissociate with translation initiator  
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Figure 2. Pim kinase downstream phosphorylation substrates and Pim kinase-regulating 
pathways.  
Pim kinases regulate multiple substrates four of the major pathways including transcription, 
translation, cell survival and cell cycle regulation.  
This figure is adapted and altered from Chen L.S. et al, Biochem Pharmacol. 2010; 80,1936-45, after 
permission granted by Biochemical Pharmacology journal to use in dissertation.  
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Figure	2.		
Adapted from Chen L.S. et al, Biochem Pharmacol. 2010; 80, 1936-45, with permission 
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eIF4E to activate cap-dependent translation process, which generates many early-response 
oncogenes including Pim kinases themselves (Gingras 2001; Trivigno 2013).  
In addition, Pim-2 is known to phosphorylate 4E-BP1 (Ser65) through an unknown 
mechanism (Tamburini 2009). Pim-2 affects cap-dependent translation independently and in parallel 
of the PI3K/Akt/mTOR pathway (Fox 2003; Amaravadi R. 2005; Hammerman 2005). Interestingly, 
PIM2 expression was associated with elevated eIF4E expression (both phospho- and total protein 
levels) compared to cells with constitutively active Akt (Hammerman 2005).  
Pim kinases and cell survival regulation 
In cell survival, Pim-1 and Pim-2 phosphorylate proapoptotic Bcl-2‒associeated death 
promoter (Bad) at Ser112, 136 and 155, where Ser112 is the dominate site (Macdonald 2006). 
Inversely, Pim-3 mostly phosphorylates Ser136 and 155 sites instead of Ser112 (Macdonald 2006). 
These phosphorylation events lead to disruption of Bad binding with antiapoptotic Bcl-XL, an anti-
apoptotic member of the Bcl-2 family. This event sequesters proapoptotic function of Bad as the 
phosphorylated protein is now bound with scaffold protein 14-3-3, and also tips the balance in favor 
of cell survival by adding more players to the anti-apoptotic reservoir (Yan 2003; Macdonald 2006). 
Notably, phosphatase 2 (PP2A) is known to dephosphorylate Bad at Ser112 to reverse the above 
phenomenon (Chiang 2003). Pim-1 is also known to bind PP2A, which leads to destruction of Pim-1 
through ubiquitylation degradation (Losman 2003).  
In addition, Pim kinase may also contribute to cell survival through intervening with cellular 
metabolism machinery such as enhancing glycolysis by phosphorylating Bad at Ser155 (Danial 
2003). Additionally, PIM2 gene expression in growth factor-regulated cell line was able to increase 
glycolytic rate and induce cell survival associated with Bad phosphorylation (Fox 2003).  
Pim kinases and cell cycle regulation 
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In addition, Pim kinases play an important role in upregulating cell cycle process. Cell cycle 
proteins cyclin-dependent kinase inhibitor 1 (p21), cyclin-dependent kinase inhibitor 1B (p27), as 
well as cdc25A/C are all known Pim kinase targets (Mochizuki 1999; Wang 2002; Morishita 2008).  
Pim-1 phosphorylates cdc25A to enhances its effect in G1/S cell cycle entry; meanwhile, 
Pim-1 inactivates p21 through phosphorylation which also contribute to G1/S progression (Swords 
2011). Pim kinases directly phosphorylate p27 to repress its activity as a tumor suppressor and G1/S 
modulator (Morishita 2008). In addition, Pim-1 phosphorylates G2/M cell cycle regulator cdc25C 
and pushes cells to enter mitosis (Bachmann 2006).  Interestingly, it was also reported that Pim-2 
induces proteasome-mediated degradation of cdc25A which leads to phosphorylation of CDK2 to 
trigger G1 cell cycle arrest (Levy 2012). Therefore, Pim kinases regulate cell cycle processes 
through promoting cell cycling, hereby enhancing tumor proliferation (Merkel 2012). 
IV. Pim kinase inhibitor 
It has been confirmed that Pim kinases gene and proteins are overexpressed in hematological 
malignancies and solid tumors, and their increased expression levels are indicative of poor prognosis 
in the clinic (Gomez-Abad 2011; Nawijn 2011). Their multitude of substrates and functions render 
them important oncogenes in these B-cell malignancies, and important drivers of lymphomagenesis 
(Chen 2010; Nawijn 2011). Importantly, Pim kinases are dispensable, confirmed by viable and fertile 
Pim triple knockout mice, making them druggable targets (Mikkers 2004).  
Pim kinase small molecular inhibitor‒SGI-1776 
Pim kinase x-ray crystallography studies discovered a unique “fold-hinge-fold” structure of 
Pim kinases that provided the foundation of highly specific Pim kinase inhibitor development. In this 
region, a proline residue was found at position 123, followed by an additional amino acid, creating 
an unusual hydrophobic pocket for ATP binding ‒a site for highly selective structure-based drug 
design (Cheney 2007; Swords 2011). Large databases of virtual compounds were used for the high-
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throughput screening, as well as predictive pharmaceutical properties calculations were performed to 
find “hits” as potential Pim kinase inhibitors (Chen 2009). Additional criteria such as solubility, 
permeability, molecular weight, drug-like properties etc. were used to narrow down the long list of 
potential hits, and imidazo[1,2-b]pyridazines structure was a final candidate, which was then used as 
the basics for developing SGI-1776 compound (Figure 3) (SuperGen,, now Astex Pharmaceuticals).  
SGI-1776 was screened against a wide range of kinases using radiolabeled biochemical 
assays, and it showed high specificity towards Pim-1, and Pim-3, as well as Fms-like tyrosine kinase 
3 (FLT-3) and transforming tyrosine kinase protein (TrkA), both are cell membrane-bound kinase 
receptors  (Chen 2009). The half-maximal inhibitory concentration (IC50) of SGI-1776 is 7 nM, 363 
nM, and 69 nM for Pim-1, -2 and -3, respectively, indicating the compound is less specific for Pim-2 
compared to the other Pim kinases  (Chen 2009).   
Other Pim kinase inhibitors 
Currently, several groups from both academia and industry are developing Pim kinase 
inhibitors, such as pan Pim kinase inhibitors SMI-4a (University of South Carolina) and AZD-1208 
(AstraZeneca plc), and GNE-652(Genentech, Inc.) and more (Beharry 2011; Keeton 2011; 
Munugalavadla 2011; Blanco-Aparicio 2012; Keeton 2012). These inhibitors are either in pre-
clinical trial (GNE-652) or clinical trial (AZD-1208), among them, AZD-1208 has shown favorable 
safety and patient tolerability in refractory AML patients.  
V. Bendamustine 
 Bendamustine is an FDA-approved second-line chemotherapeutic agent for treating B-cell 
lymphoma and CLL (National Cancer Institute). Bendamustine hydrochloride (TRENDA®, 
Cephalon, Inc.) is the intravenously-administrated drug that is used to treat indolent B-cell 
lymphoma that has progressed during the six months of rituximab or rituximab-containing regimens 
(National Cancer Institute).  
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Figure 3. Chemical structure of Pim kinase inhibitor, SGI-1776. 
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Bendamustine is not a novel anticancer drug per se, as it was first synthesized in the 1960s and was 
quite extensively in Europe during the following decades, but in the US, it was not wildly used as 
much and was not approved by the FDA until 2008 (Gandhi 2009).   
Bendamustine is an alkylating agent with the active component of nitrogen mustard (Figure 
4) (Leoni 2008). Bendamustine is known to induce intra- and inter-strand DNA crosslinks, leading to 
initiation to DNA repair response, which is a slower process compared to other alkylating agents 
(Gandhi 2009; Leoni 2011). These types of DNA damage causes impaired DNA replication, and also 
disrupts transcription process in both replicating and quiescent cells, making it a drug-of-choice for 
indolent diseases (Leoni 2008; Gandhi 2009). Bendamustine presents a unique mechanism of action 
in cell killing, as it activate p53-dependent DNA damage stress response, producing higher levels of 
p21 and Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) compare to other alkylating 
agents (Leoni 2011).  
In addition, release of apoptosis-inducing factor (AIF) from mitochondria following 
bendamustine treatment was also observed, and that oxidative stress is an important mediator of 
caspase-independent cell killing in CLL and MCL (Roue 2008). Importantly, bendamustine does not 
show cross-resistance with other alkylating agents, and shows synergism with nucleoside analogs 
(Roue 2008; Gandhi 2009).  
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CHAPTER 2: Material and methods 
Cell lines 
MCL cell lines JeKo-1, Mino, Granta 519 and SP-53 were obtained from Dr. Hesham Amin 
at MD Anderson Cancer Center. JeKo-1, Mino, and SP-53 were maintained in RPMI-1640 medium 
(Corning Cellgro for JeKo-1 and SP-53, American Type Culture Collection for Mino) supplemented 
with 10% fetal bovine serum (FBS; Invitrogen) for JeKo-1 or 20% FBS for Mino and SP-53 cells. 
Granta 519 was maintained in Dulbecco modified Eagle medium with high glucose (DMEM, 
Corning Cellgro) with 20% FBS. Characterization of these cell lines showed high levels of cyclin D1, 
c-Myc, and B-cell lymphoma 2 (Bcl-2) family members such as induced myeloid leukemia cell 
differentiation protein (Mcl-1), Bcl-2 and B-cell lymphoma-extra large (Bcl-XL) (Amin 2003). These 
cell lines were authenticated using an AmpF/STR Identification Kit (Applied Biosystems) and 
routinely tested for Mycoplasma contamination using a MycoTect kit (Invitrogen). Experiments were 
conducted in cells with less than 20 passages, and maintained at logarithmic growth concentration 
between 105 cells/mL and 106 cells/mL determined by a Coulter channelyzer (Beckman Culter, Inc.) 
with less than 10% endogenous cell death confirmed by flow cytometry.  
Primary cells from MCL and other B-cell lymphoma patients 
Samples were obtained from lymphoma tissue bank at MD Anderson Cancer Center or 
healthy donors after informed consents through institutional review board‒approved protocols that 
were in agreement with the Declaration of Helsinki. Peripheral blood mononuclear cells (PBMCs) 
were isolated from fresh aphesis or whole blood samples using the standard Ficoll-Hypaque 
(Invitrogen) density gradient centrifugation. A Coulter chanelyzer was used to determine cell count 
and size for each experiment. Primary cells were cultured in RPMI-1640 medium with 10% FBS, at 
densities between 107 cells/mL and 108 cells/mL during experiments. Endogenous cell death levels 
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were determined before each experiment using flow cytometry, and only samples with less than 40% 
inherent cell death were used for experiments.  
Drugs  
SGI-1776 was provided by SuperGen (now Astex Pharmaceuticals, Inc.). Bendamustine 
hydrochloride was originally obtained from Cephalon (now Teva Pharmaceuticals Industries, Ltd.) 
and later purchased from Selleckchem, USA. SGI-1776 was shipped in powder form and they were 
stored in a desiccator at room temperature. Powders were dissolved in dimethyl sulfoxide (DMSO) 
immediately before use and stored at -20°C. Bendamustine hydrochloride was dissolved in DMSO 
and stock solutions were made and stored in -80°C.  
In our investigations, micromolar concentrations of SGI-1776 and bendamustine were used, 
and for both drugs, the highest concentration was 10μM. These concentrations were chosen based on 
previous publications. For SGI-1776, high percentage (>85%) of the drug bound to human plasma 
proteins and FBS in the cell media, that micromolar concentrations of SGI-1776 are needed to reach 
nanomolar concentrations of free drug (Chen 2009). 
Apoptosis assays  
Cells were treated with DMSO alone or drugs, then cells (106 cells per experiment) were 
washed with PBS and then incubated with annexin V (BD Pharmingen) followed by propidium 
iodine (PI) in annexin binding buffer. After 15min of incubation, annexin V/PI positivity for cell 
death was measured using FACSCalibur flow cytometer (BD Biosciences).  
Cell cycle assays 
 DMSO or drug-treated cells (>106 cells per experiment) were washed with PBS, and then 
cells were fixed overnight at 4°C using 70% ethanol. Cells were then removed from ethanol by 
centrifugation and washed twice with PBS, followed by 15min co-incubation with 25µg/mL PI and 
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2.5µg/mL DNAse-free RNAse (Roche Diagnostics) at room temperature. PI positivity was then 
measured by flow cytometry for cell cycle profiling.  
Immunostaining of γ-H2AX  
Post-treatment MCL cell lines (106 or more cells) were washed twice with PBS, and then 
fixed with ice-cold 70% ethanol overnight at 4°C. Ethanol was removed by centrifugation and then 
cells were washed once with PBS and twice with PBS with 1% bovine serum albumin (BSA) to 
avoid cell loss. After washing, cells were incubated with primary phospho-Histone 2AX (Ser139) or 
γ-H2AX antibody (EMD Millipore) for 2hr at room temperature with gentle shaking, and then were 
washed three times with PBS with 1% BSA plus 0.1% NP-40 (Sigma-Aldrich Corp). Cells were then 
incubated with Alexa Fluor mouse IgG secondary antibody (488 goat, Invitrogen Corp) for 1hr at 
room temperature protected from light, followed by three washes with PBS with 1% BSA and 0.1% 
NP-40. Finally, cells were co-incubated with 10µg/mL PI and 2.5µg/mL DNAse-free RNAse for 
30min at room temperature, and then they were analyzed by flow cytometry. The cells showed 
upward shift of florescent signals compared to baseline were marked as percent positive for DNA 
damage.  
Immunohistochemistry  
Formalin-fixed, paraffin-embeded MCL tissue sections were used for immunohistochemical 
analysis. Heat-induced antigen retrieval (Dako target retrieval pH6) was used following a manual 
procedure. Pim-1, Pim-2 and Pim-3 antibodies (all rabbit; Abcam plc) were used to stain the tissue 
for Pim kinase protein expression. Detection of Pim kinase expression was performed with 
biotinylated secondary antibody, horseradish peroxidase, and 3,3′-diaminobenzidine as a chromogen 
(Abcam), then tissue slides were counterstained with hematoxylin. Meanwhile, appropriate negative 
and positive control slides were run in parallel. Photographs of the results were taken using an 
Olympus U-TV0 camera (Olympus Corporation) mounted on an Olympus BX41 microscope. 
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Hematoxylin staining image was obtained at 100× magnification (objective Plan N 10×) while Pim 
kinases staining images were obtained at 400× magnification (objective Plan N 40×). Images were 
processed using CellSens software (Olympus).  
Macromolecule synthesis assays 
MCL cell lines or B-cell lymphoma primary samples were incubated with [methyl- 3H]-
thymidine, [5,6- 3H]-uridine or [4,5- 3H]-L-leucine (1.0mCi/mL stock; Moravek Biochemicals) for 
30-45min of each experiment. Cells from cell lines (106) or primary samples (107) were seeded in 
each well of a 12-welled plate, respectively, and each treatment was done in triplicate. Various 
concentrations of radioactive nucleosides were used in cell lines (0.8mCi/mL) and in primary 
samples (4mCi/mL). The incorporated radioactivity was used to measure DNA, RNA and protein 
synthesis, using a Packard Tri-Carb liquid scintillation analyzer (GMI, Inc) as previously described 
(Balakrishnan 2005).  
Gene expression assays 
Total RNA from MCL cell lines and B-cell lymphoma primary cells was extracted using the 
RNAeasy mini kit manually or QIAcube automated system (Qiagen N.V.). NanoDrop ND 1000 
spectrophotometer (Thermo Fisher Scinetific) was used to quantify RNA. RNA extract was diluted 
to a desirable concentration (30-50ng/mL for target genes, and 5ng/mL for 18S control), and then 
mixed with a 1-step TaqMan reverse transcription polymerase chain reaction (RT-PCR) master mix 
(Applied Biosystems). Gene expression levels were measured with an ABI prism 7900 sequence 
detection system (Applied Biosystems). Primers and probes for PIM1 (Hs01065498_m1), PIM2 
(Hs00179139_m1), PIM3 (Hs00420511_g1), MCL1 (Hs00172036_m1), MYC (Hs00153408_m1), 
CCDN1 (Hs00765553_m1), and 18S (4333760) (Applied Biosystems) were used to detect 
expression levels of the corresponding genes. Each experiment was performed in triplicate and 
relative gene expression levels were normalized to 18S, an endogenous control.  
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Protein expression assays with immunoblots 
Control and drug-treated MCL cell lines and B-cell lymphoma primary cells were lysed 
using radioimmunoprecipitation assay buffer (RIPA; Upstate Biotechnology) and sonication, and 
then protein concentration was measured using Bio-Rad DC protein assay (Bio-Rad Laboratories). 
Total protein lysates (30-50µg) were loaded into 10%, 12% or 4-12% bis-tris polyacrylamide gels 
(Bio-Rad Laboratories) and transferred to nitrocellulose membranes (GE Osmonics Labstore), then 
probed with targeted primary antibodies at 4°C overnight (Table 1). Membranes were then washed 
and incubated with infrared-labeled secondary antibodies for 1hr at room temperature, and then the 
protein bands were visualized using an Odyssey infrared imager (LI-COR Biosciences). 
siRNA transfection 
PIM1, PIM2 genes were knocked down individually or in combination by corresponding 
human siRNAs for PIM1 (S10527) and PIM2 (S21749) (Ambion/Invitrogen). Negative control 
siRNA #1 (AM4611; Ambion/Invitrogen) was also used for each set of experiments. siRNA 
transfection was performed using Amaxa Nuceofector I device (Lonza Group) with Amaxa cell line 
nucleofector kit V (Lonza Group) for electroporation. After transfection, cells were placed back to 
37°C incubator for 24hr, and then they were harvested and tested for viability and. For each 
experiment, 150µM of siRNA (both negative control and treatment) was used to knockdown each 
gene and 150µM of siGLO red transfection indicator (Dharmacon Inc) was used to detect 
transfection efficiency.  Cell type-specific protocols were optimized for transfection efficiency 
(>60%) and cell viability (>30%).  
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Table 1.  
 
 
 
 
Table 1. Primary antibodies used in immunoblot analyses and their sources. 
  
 Primary Antibodies Companies   
Primary 
Antibodies Companies  
1 Phospho-Bad (Ser112) 
Cell Signaling 
Technology,  
Beverly, MA 
10 GAPDH 
Cell Signaling 
Technology,  
Beverly, MA 
2 Total Bad 
Cell Signaling 
Technology,  
Beverly, MA 
11 Phospho-H2AX (Ser139) 
EMD Millipore, 
Billerica, MA 
3 Bcl-2 Dako,  Carpinteria, CA 12 
Phospho-Histone 
H3 (Ser10) 
EMD Millipore, 
Billerica, MA  
4 Bcl-XL 
BD Transduction 
Laboratories, 
Lexington, KY 
13 Total Histone H3 
Cell Signaling 
Technology,  
Beverly, MA 
5 Phospho-c-Myc (Ser62) 
Abcam, 
Cambridge, MA 14 Mcl-1 
Santa Cruz 
Biotechnology,  
Santa Cruz, CA 
6 Total c-Myc  (clone C33) 
Santa Cruz 
Biotechnology,  
Santa Cruz, CA 
15 PARP BD Biosciences,  Franklin Lakes, NJ 
7 Cyclin D1 
Santa Cruz 
Biotechnology,  
Santa Cruz, CA 
16 Cleaved PARP  (Asp214) 
Cell Signaling 
Technology,  
Beverly, MA 
8 
Phospho-
Cdc25C 
(Ser216) 
Cell Signaling 
Technology,  
Beverly, MA 
17 Pim-1 (clone 12H8) 
Santa Cruz 
Biotechnology,  
Santa Cruz, CA 
 Cdc25C Upstate/Millipore, Billeria, MA 18 Pim-2 
Sigmal-Aldrich,  
St. Louis, MO 
8 Phospho-4E-BP1 (Thr37/46) 
Cell Signaling 
Technology,  
Beverly, MA 
19 Pim-3 Abgent,  San Diego, CA 
9 Total 4E-BP1 
Santa Cruz 
Biotechnology,  
Santa Cruz, CA 
20 XIAP BD Biosciences, Franklin Lakes, NJ 
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Data analyses 
All plots were prepared and analyzed using GraphPad Prism software version 5 (GraphPad 
Software, Inc). All cell line data were performed in triplicates and were presented as mean value ± 
standard error of the mean (SEM). DMSO was used as vehicle control for all drug treatments. For 
single drug treatment experiments, most data were analyzed by the Student paired, 2-tailed t-test. For 
combination drug treatments, fractional analysis was used to determine if the combination methods 
lead to less than, equal to or more than additive effect on induction of apoptosis, or similarly on 
increase of γ-H2AX phosphorylation, or thymidine, uridine and leucine incorporation inhibition. 
Phosphorylated and total protein expression levels detected by immunoblots were quantified using 
Odyssey software for the Odyssey Infrered Imaging System (LI-COR Biosciences), and then 
normalized to DMSO control using GraphPad Prism software. For immunoblot analyses, a ratio of 
phosphorylated protein to total protein level was calculated for the phosphorylated proteins, whereas 
a ratio of protein to GAPDH level was carried out for total protein only targets.  
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CHAPTER 3. SGI-1776 single agent therapy in MCL 
It has been demonstrated that Pim kinases are overexpressed in MCL and that Pim kinases 
are involved with regulation of transcription, translation, cell death and cell cycle regulation (Figure 
2). Importantly, Pim-1 overexpression is negatively related to MCL patient outcome during therapy 
(Hsi 2008). In addition, Pim kinases are proven to be druggable targets as mice lacking all three Pim 
kinases were viable and fertile (Mikkers 2004; Swords 2011). Based on this background we aim to 
evaluate the potential utility of SGI-1776 in MCL and that inhibition of phosphorylation of 
downstream substrates will disrupt transcriptional, translational, and cell cycle processes and while 
promoting cell death.  
To test these hypotheses, we propose the following two aims: 
Aim 1) Analyze the biological consequences of SGI-1776 in MCL cells.  
Aim 2) Identify the biological function of Pim kinases in their signaling pathways and 
primary biomarkers impacted by SGI-1776 in MCL cells.  
Aim 1. Analyze the biological consequences of SGI-1776 in MCL cells.  
Aim  1.1. Expression of Pim kinases in MCL cell lines and primary tissue samples.  
 Expression of Pim kinases in MCL cell lines.  
Immunoblots of untreated or DMSO-treated JeKo-1 and Mino cells were performed to 
determine the expression levels of Pim-1, -2 and -3 (Figure 5). At least 106 log-phased cells of both 
cell lines were harvested to extract protein lysates, and GAPDH control was used for each Pim 
kinase detected. For both Pim-1 and Pim-2, multiple bands were detected and for Pim-3, one band 
was detected. These results are consistent with reports of alternative translation start sites of Pim-1 
and Pim-2 (Nawijn 2011).   
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Expression of Pim kinases in MCL primary tissue samples.  
A series of MCL patient paraffin-embedded tissue sections were obtained for 
immunohistochemical analysis to detect Pim kinase expression (Figure 6). These tissues were stained 
with Pim kinase antibodies and both negative and positive controls are used in parallel. Reactivity 
for all three Pim kinases was detected in 92% of the cases, with variable intensities for different Pim 
kinases (Table 2). Data showed that Pim-1 and Pim-2 expressed stronger intensity than Pim-3; 
meanwhile, Pim-1 was mostly nuclear and cytoplasmic, whereas Pim-2 was mostly cytoplasmic and 
Pim-3 was mostly nuclear (Table 2).  
In addition, it was noticeable that in our Pim kinases expression study using paraffin-
embedded MCL lymph node tissue samples, we detected a higher-than-usual incidence of Pim 
kinase expression compared to the literature (Hogan 2008; Gomez-Abad 2011). 
 Aim 1.2. Detection of SGI-1776 induced dose- and time-dependent apoptosis in MCL cell lines. 
 Induction of dose-dependent apoptosis by SGI-1776 in MCL cell lines.  
Effect of SGI-1776 in apoptosis was evaluated using MCL cell lines JeKo-1, Mino, Granta 
519 and SP-53. All four cell lines were either untreated, or treated with DMSO or increasing 
concentrations of SGI-1776 (0.1, 1, 3, 5 10μM) for 24hr.  
Following treatment, MCL cells were harvested and were washed with PBS and then stained 
with Annexin V/PI, and levels of apoptosis were measured by flow cytometry. Dose-dependent 
induction of apoptosis in JeKo-1 (Figure 7), Mino (Figure 8), Granta 519 (Figure 9) and SP-53 
(Figure 10) are indicated by the increasing number of cells in the lower and upper right quadrants 
paired with decreasing number of cells in the lower left quadrants. Percentages of apoptotic cells 
resulting from each drug concentration in each of the four cell lines indicated a dose-dependent 
increase of apoptosis levels (Figure 11A).  
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Figure 6. Expression of three Pim kinases in MCL primary tissue samples.  
Histologic sections of paraffin-embedded MCL tissue sample were immunohistochemically stained 
with Hematoxylin and eosin, and were then stained with anti-Pim-1, -2, and -3 antibodies and 
counterstained with hematoxylin. The tissue sample slides were visualized using an Olympus U-TV0 
camera.  
  
H & E Pim-1
Pim-2 Pim-3
MCL primary tissue samples 
Figure 6.  
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Table 2.  
 
 
 
 
MCL samples, 
Number positive for kinase/number analyzed 
Pim-1 11/12 
Pim-2 11/12 
Pim-3 11/12 
 
 
 
Table 2. Incidence of Pim kinases expressions in immunohistochemically stained MCL primary 
tissue samples.  
Data presented as number positive for kinase/total number analyzed. 
 
Reactivity: 
PIM1: Faint to moderate staining; mostly nuclear and cytoplasmic 
PIM2: Strong; mostly cytoplasmic 
PIM3: Very faint staining, mostly nuclear 
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Figure 7. Increase of apoptosis by SGI-1776 treatment in JeKo-1 cells measured by Annexin 
V/PI assay.   
JeKo-1 cells were either untreated, or treated with DMSO, or different doses of SGI-1776 (0.1, 1, 3, 
5 or 10μM) for 24hr. Cells were harvested and then stained with Annexin V for 15mins followed by 
5mins of PI. Levels of apoptosis for each treatment was detected using flow cytometry, where 
apoptotic cells were indicated by the cell population present in lower right, upper left, as well as 
upper right quadrants. Experiments were performed in triplicate and the panel graphs shown are 
representative of cell death at different concentrations of SGI-1776.   
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Figure 7.  
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Figure 8. Increase of apoptosis by SGI-1776 treatment in Mino cells measured by Annexin 
V/PI assay.   
Mino cells were either untreated, or treated with DMSO, or different doses of SGI-1776 (0.1, 1, 3, 5 
or 10μM) for 24hr. Cells were harvested and then stained with Annexin V for 15mins followed by 
5mins of PI. Levels of apoptosis for each treatment was detected using flow cytometry, where 
apoptotic cells were indicated by the cell population present in lower right, upper left, as well as 
upper right quadrants. Experiments were performed in triplicate and the panel graphs shown are 
representative of cell death at different concentrations of SGI-1776.    
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Figure 9. Increase of apoptosis by SGI-1776 treatment in Granta-519 cells measured by 
Annexin V/PI assay.   
Granta-519 cells were either untreated, or treated with DMSO, or different doses of SGI-1776 (0.1, 1, 
3, 5 or 10μM) for 24hr. Cells were harvested and then stained with Annexin V for 15mins followed 
by 5mins of PI. Levels of apoptosis for each treatment was detected using flow cytometry, where 
apoptotic cells were indicated by the cell population present in lower right, upper left, as well as 
upper right quadrants. Experiments were performed in triplicate and the panel graphs shown are 
representative of cell death at different concentrations of SGI-1776.   
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Figure 10. Increase of apoptosis by SGI-1776 treatment in SP-53 cells measured by Annexin 
V/PI assay.   
SP-53 cells were either untreated, or treated with DMSO, or different doses of SGI-1776 (0.1, 1, 3, 5 
or 10μM) for 24hr. Cells were harvested and then stained with Annexin V for 15mins followed by 
5mins of PI. Levels of apoptosis for each treatment was detected using flow cytometry, where 
apoptotic cells were indicated by the cell population present in lower right, upper left, as well as 
upper right quadrants. Experiments were performed in triplicate and the panel graphs shown are 
representative of cell death at different concentrations of SGI-1776.   
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Figure 11. Induction of dose-dependent apoptosis by SGI-1776 in MCL cell lines.  
(A) Dose-dependent annexin-V/PI positivity induced by SGI-1776 in MCL cell lines. Four MCL cell 
lines (JeKo-1, Mino, Granta 519 and SP-53) were treated with DMSO alone or with a range of doses 
(0.1, 1, 3, 5 or 10μM) of SGI-1776 for 24hr, and then stained with annexin-V/PI. Apoptosis level, 
indicated by annexin-V/PI positivity was determined by flow cytometry. (B) Apoptosis level in 
JeKo-1 and Mino was confirmed by the presence and intensity of cleaved PARP on an immunoblot 
assay. SGI-1776 was used to treat JeKo-1 and Mino for 24hr in the concentrations mentioned above, 
the protein lysates extracted were used for immunoblot analysis. Experiments were performed in 
triplicate and results shown are average cell death ± SEM.  
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Treatment with 0.1μM SGI-1776 for 24hr resulted in low levels of apoptosis, whereas an average of 
1%-15% Annexin V/PI positivity was detected at 1μM, 5%-40% at 3μM, 15%-60% at 5μM and 
60%-80% at 10μM of SGI-1776 treatments. 
Induction of apoptosis was also confirmed by immunoblot analysis of PAPR cleavage 
following dose-dependent SGI-1776 treatments in JeKo-1 and Mino (Figure 11B). In both cell lines, 
cleaved PARP was detected with 5μM and with greater intensity with10μM SGI-1776 treatments.  
Induction of time-dependent apoptosis by SGI-1776 in MCL cell lines. 
 JeKo-1 and Mino cell lines were treated with 10μM of SGI-1776 for various times then cell 
death levels were measured using flow cytometry (Figure 12A). Average apoptosis levels in JeKo-1 
were 5%, 17%, 33%, 50% and 89% for 2, 4, 8, 16, and 24hr of SGI-1776 treatment, respectively; 
whereas in Mino, 2%, 3%, 5%, 10% and 38% of apoptosis were measured.   
 To confirm the occurrence of apoptosis induction, PARP cleavage was measured using 
immunoblots and in both cell lines, visible cleaved PARP band was detected as early as 4hr of SGI-
1776 treatment (Figure 12B).  
Aim 2. Identify the biological function of Pim kinases in their signaling pathways and primary 
biomarkers impacted by SGI-1776 in MCL cells.   
Aim 2.1. Effect of SGI-1776 on Pim kinase phosphorylation targets in MCL cell lines. 
In order to confirm whether SGI-1776 act on Pim kinases and inhibit their kinase function, 
and also to identify the specific pathways inhibited by this drug, we investigated the effect of SGI-
1776 on known Pim kinase phosphorylation targets ‒c-Myc, Histone H3, 4E-BP1 and Bad, and 
analyzed the changes of their phosphorylation levels. MCL cell lines JeKo-1 and Mino were treated 
with SGI-1776 in dose-dependent fashion, and immunoblot analyses were performed to detect both 
phospho- and total protein expression levels.    
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Figure 12. Induction of time-dependent apoptosis by SGI-1776 in MCL cell lines.  
(A) Time-dependent annexin-V/PI positivity induced by SGI-1776 in MCL cell lines. JeKo-1 and 
Mino cells were treated with DMSO alone or with 10μM SGI-1776 for different time points (0.5, 1, 
2, 4, 8, 16, or 24hr), stained with annexin-V/PI, and then apoptosis levels were measured by flow 
cytometry. (B) Apoptosis levels in JeKo-1 and Mino was confirmed by immunoblot analysis of 
cleaved PARP. Both MCL cell lines were treated with 10μM SGI-1776 for times indicated above, 
and protein lysates extracted from cells were used for immunoblot analysis. Experiments were 
performed in triplicate and results shown are average cell death ± SEM. 
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Effect of SGI-1776 on Pim kinase target and transcription regulator c-Myc in MCL cell lines. 
JeKo-1 and Mino cells were either untreated, or treated with DMSO, or with various doses 
of SGI-1776 (0.1, 1, 3, 5, 10μM) for 24hr, then 2x106 cells were harvested and total protein lysates 
were extracted for immunoblot analysis. In cell lines, c-Myc (Ser62) and total c-Myc levels were 
detected, and each protein band was quantitated (Figure 13A). GAPDH was measured as loading 
control and the levels were relatively even except for JeKo-1 with 10μM SGI-1776 treatment, where 
extensive apoptosis was observed (Figures 13, 14).  
Ratios of c-Myc (Ser62) to total c-Myc levels were calculated and results were normalized to 
DMSO control (Figure 13B). A dose-dependent decrease of phospho- to total c-Myc ratio was 
observed in both cell lines, whereas JeKo-1 demonstrated greater decrease compared to Mino.   
Effect of SGI-1776 on Pim kinase target and transcription regulator Histone H3 in MCL cell 
lines. 
JeKo-1 and Mino cells were untreated, or treated with DMSO or SGI-1776 in above 
concentrations for 24hr, and then cells were harvested and total protein lysates were extracted for 
immunoblot analysis. Histone H3 (Ser10) and total Histone H3 proteins were detected and 
quantitated (Figure 14A). Normalized ratios of Histone H3 (Ser10) to total Histone H3 levels 
indicated a dose-dependent decrease only occurred in JeKo-1 but not in Mino (Figure 14B). 
Effect of SGI-1776 on Pim kinase target and translation regulator 4E-BP1 in MCL cell lines. 
Untreated, or DMSO-treated, along with dose-dependent SGI-1776-treated JeKo-1 and Mino 
cells were harvested after 24hr, and then total protein lysates were extracted for 4E-BP1 immunoblot 
analysis. 4E-BP1 (Thr37/46) and total 4E-BP1 proteins were both detected and quantitated (Figure 
15A). Normalized ratios of 4E-BP1 (Thr37/46) to total 4E-BP1 levels indicated a dose-dependent 
decrease in both JeKo-1 and Mino cell lines (Figure 15B).  
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Figure 13. Effect of SGI-1776 on Pim kinase target, c-Myc, in MCL cell lines.  
JeKo-1 and Mino cells were untreated or treated with DMSO alone or with different doses of SGI-
1776 (0.1, 1, 4, 5, 10µM) for 24hr. (A) Protein lysates were analyzed using immunoblot to detect the 
expression levels of c-Myc (Ser62) and total c-Myc. (B) Quantitation of immunoblots for each cell 
line was performed by measuring ratios of phospho-c-Myc to total c-Myc for each SGI-1776 
treatment, and then ratios from each treatment were normalized to the result of DMSO-treated cells. 
Experiments were performed in triplicate and results were shown as average ratios ± SEM. 
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Figure 14. Effect of SGI-1776 on Pim kinase target, Histone H3, in MCL cell lines.  
JeKo-1 and Mino cells were untreated or treated with DMSO alone or with different doses of SGI-
1776 (0.1, 1, 4, 5, 10µM) for 24hr. (A) Protein lysates were analyzed using immunoblot to detect the 
expression levels of Histone H3 (Ser10) and total Histone H3. (B) Quantitation of immunoblots for 
each cell line was performed by measuring ratios of phospho-Histone H3 to total Histone H3 for 
each SGI-1776 treatment, and then ratios from each treatment were normalized to the result of 
DMSO-treated cells. Experiments were performed in triplicate and results were shown as average 
ratios ± SEM. 
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Figure 15. Effect of SGI-1776 on Pim kinase target, 4E-BP1, in MCL cell lines.  
JeKo-1 and Mino cells were untreated or treated with DMSO alone or with different doses of SGI-
1776 (0.1, 1, 4, 5, 10µM) for 24hr. (A) Protein lysates were analyzed using immunoblot to detect the 
expression levels of 4E-BP1 (Thr37/46) and total 4E-BP1. (B) Quantitation of immunoblots for each 
cell line was performed by measuring ratios of phospho-4E-BP1 to total 4E-BP1 for each SGI-1776 
treatment, and then ratios from each treatment were normalized to the result of DMSO-treated cells. 
Experiments were performed in triplicate and results were shown as average ratios ± SEM. 
 
 
 
  
 
 
 
 
 
 
p-
4E
-B
P1
/to
ta
l 4
E-
B
P1
%
of
C
on
tr
ol
(D
M
SO
)
Figure 
A 
B 
0
0.0
0.5
1.0
0.1
%
  o
f C
on
tr
ol
 (D
M
SO
)
15.  
1 3
J
SGI-1
 
5
eKo-1
776 (M)
49 
 
10 0
0.0
0.5
1.0
0
p-
4E
-B
P1
/to
ta
l 4
E-
B
P1
%
  o
f C
on
tr
ol
 (D
M
SO
)
.1 1
S
3 5
Mino
GI-1776 (M)
 
10
50 
 
Effect of SGI-1776 on Pim kinase target and cell survival regulator Bad in MCL cell lines. 
JeKo-1 and Mino cells were untreated or treated with DMSO or SGI-1776 in varies 
concentrations mentioned above, or remain untreated for 24hr, cells were then harvested and total 
protein lysates were extracted for immunoblot analysis of Bad protein (Figure 16A). Bad (Ser112) 
and total Bad proteins levels indicated a dose-dependent decrease in JeKo-1 but not in Mino (Figure 
16B). 
Aim 2.2. Effect of SGI-1776 on RNA synthesis and of MCL1 gene expression levels in MCL cell 
lines. 
c-Myc phosphorylation was decreased in both JeKo-1 and Mino cell lines, which suggest a 
possible role in repressing c-Myc-driven transcription process in MCL cells by SGI-1776. Based on 
this evidence, we hypothesized that RNA synthesis along with short-lived mRNAs expression levels 
would also be affected.   
Effect of SGI-1776 on global RNA synthesis in MCL cell lines.  
  MCL cell lines JeKo-1, Mino, Granta 519 and SP-53 were treated with DMSO or increasing 
concentrations of SGI-1776 (0.1, 1, 3, 5, 10μM) for 24hr, while JeKo-1 and Mino cells were treated 
with DMSO or 10μM of SGI-1776 for various time points (0.5, 1, 2, 4, 8 16, 24hr). In the last 30min 
prior to harvesting, radioactively-labeled uridine was added for incorporation into the newly 
synthesized RNA. The incorporated radioactivity was measured using scintillation counter, and 
results were measured as DPM/cell normalized to DMSO control (Figure 17).  
In the dose-dependent experiments with various concentrations of SGI-1776 over a 24hr 
period, a steady decrease of RNA synthesis levels compared to DMSO control was detected in all 
three cell lines except for Mino. In Mino cells, the RNA synthesis level increased under low doses 
(0.1 and 1μM) of SGI-1776 treatment and then started to decrease at higher doses, and eventually 
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Figure 16. Effect of SGI-1776 on Pim kinase target, Bad, in MCL cell lines.  
JeKo-1 and Mino cells were untreated or treated with DMSO alone or with different doses of SGI-
1776 (0.1, 1, 4, 5, 10µM) for 24hr. (A) Protein lysates were analyzed using immunoblot to detect the 
expression levels of Bad (Ser112) and total Bad. (B) Quantitation of immunoblots for each cell line 
was performed by measuring ratios of phospho-Bad to total Bad for each SGI-1776 treatment, and 
then ratios from each treatment were normalized to the result of DMSO-treated cells. Experiments 
were performed in triplicate and results were shown as average ratios ± SEM. 
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Figure 17. Inhibition of global RNA synthesis by SGI-1776 in MCL cell lines. 
(A)MCL cell lines JeKo-1, Mino, Granta 519 and SP-53 cells were treated with DMSO or with 
different doses of SGI-1776 (0.1, 1, 4, 5, 10µM) for 24hr. (B)JeKo-1 and Mino cells were treated 
with DMSO or 10µM of SGI-1776 for different time periods (0.5, 1, 2, 4,  8, 16, 24hr). For both sets 
of experiments, MCL cells were co-incubated with [5,6- 3H]-uridine for 30min before harvesting, 
then radioactivity incorporated into the cells were measured using scintillation counter. DPM/cell 
was calculated and normalized to DMSO-treated cells. Experiments were done in triplicates and 
results were shown as average percentages ± SEM.  
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went down to 40% of DMSO control at 10μM (Figure 17A). Very similar decrease patterns were 
detected in JeKo-1 and Granta 519 cells, with slow decrease at lower doses of SGI-1776 (less than 
3μM), and faster decrease at higher doses, showing 60%-75%, 45%-57% and 22%-28% of DMSO 
control at 3, 5 and 10μM of SGI-1776, respectively. Meanwhile, in SP-53, the highest sensitivity that 
dramatic decrease (>20%) was observed at 0.1μM of SGI-1776 and then leveled with other cell lines, 
showing about 28% of DMSO control by 10μM of SGI-1776.  
 In the time-dependent experiments with various times with 10μM of SGI-1776 over a 24hr 
period, there was a significant decrease of RNA synthesis in both JeKo-1 and Mino cells at short 
time points, reaching almost 50% of DMSO by 1hr (Figure 17B). However, RNA synthesis in both 
cell lines recovered to 60%-75% of control by the 2nd hour, and slowly decreased after that. By 24hr, 
both went down to 40% of DMSO control.  
Effect of SGI-1776 on MCL1 gene expression levels in MCL cell lines.  
 To test the effect of SGI-1776 in short-lived mRNAs expression levels, we carried out 
experiments to analyze the change of MCL1 level, an short-lived oncogene known to be 
overexpressed and play a role in anti-apoptosis in MCL cell lines (Amin 2003; Khoury 2003).   
 JeKo-1 and Mino cells were treated with DMSO or dose- or time-dependent SGI-1776 for 
24hr, using the concentrations and time points mentioned above (Figure 18A, B). Upon treatments of 
SGI-1776, cells were harvested and total RNA was extracted for RT-PCR experiment. SGI-1776 
treatment resulted in both dose- and time-dependent decrease of MCL1 mRNA levels in JeKo-1 and 
Mino cells, with more prominent results shown in JeKo-1.  
In the dose-dependent experiments with various concentrations of SGI-1776 over a 24hr 
period, MCL1 mRNA level in JeKo-1 cells decreased by 35% and 38% compared to DMSO control 
at 3 and 5μM of SGI-1776 treatment, respectively.  
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Figure 18. Reduction of MCL1 mRNA expression levels by SGI-1776 treatment in MCL cell 
lines.  
(A)MCL cell lines JeKo-1, Mino cells were treated with DMSO or with increasing doses of SGI-
1776 (0.1, 1, 4, 5, 10µM) for 24hr. (B)JeKo-1 and Mino cells were treated with DMSO or 10µM of 
SGI-1776 for different time periods (0.5, 1, 2, 4,  8, 16, 24hr). Total RNA was extracted and 
quantified. Isolated RNA was analyzed by real-time RT-PCR with primers and probes for MCL1 
mRNA. Each MCL1 gene expression level measured was normalized to 18s endogenous control and 
each set of experiment was normalized to DMSO experiment control. All experiments were done in 
triplicate results were shown as average ratios ± SEM. 
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The 24hr treatment of 10μM SGI-1776 lead to apoptosis level that is too extensive that there were 
not enough cells to be harvested for this particular experiment. In Mino cells, less extensive yet 
gradual decrease of MCL1 mRNA level was detected, and the MCL1 expression levels reached 65% 
and 55% of control at 3 and 5μM, respectively (Figure 18A).  
In the time-dependent experiments with various times of 10μM SGI-1776 over a 24hr period, 
a rapid and dramatic decrease of MCL1 mRNA expression levels were detected in JeKo-1 cells, 
showing a reduction by 42% of control within 30min, and then further decreased by 73% of control 
in 1hr. The MCL1 expression levels continued to decrease after 3hr, and after 4 and 24hr, only 12% 
of MCL1 mRNA remained. In Mino cells, there was an initial increase of MCL1 mRNA expression 
during the first hour of treatment, which then started to decrease to about 50% of control after 5hr 
and finally decreased to 14% of control after 24hr (Figure 18B). 
Aim 2.3. Effect of SGI-1776 on anti-apoptotic protein expression levels in MCL cell lines.  
Our observation of decrease of 4E-BP1 phosphorylation in both JeKo-1 and Mino cells 
indicated that cap-dependent translation is negatively affected by SGI-1776 (Richter 2005). We also 
detected both dose- and time-dependent decrease of MCL1 mRNA levels in these MCL cell lines 
(Figure 18). Hence, we hypothesize that the expression levels of short-lived anti-apoptotic Mcl-1 
protein would be decrease due to SGI-1776 treatment.  
Effect of SGI-1776 on Mcl-1 protein expression levels in MCL cell lines.  
  To test this hypothesis, we evaluated the changes of short-lived Mcl-1 protein level, a 
known onco-protein in MCL (Khoury 2003). JeKo-1 and Mino cells were treated with various doses 
of SGI-1776 described and Mcl-1 protein were measured using immunoblots (Figure 19A), and 
normalized using GAPDH compared to DMSO control (Figure 19B).  
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Figure 19. Dose-dependent reduction of Mcl-1 protein expression levels by SGI-1776 treatment 
in MCL cell lines.  
(A)MCL cell lines JeKo-1, Mino cells were treated with DMSO or with different doses of SGI-1776 
(0.1, 1, 4, 5, 10µM) for 24hr. Protein lysates were analyzed using immunoblot to detect the 
expression levels of Mcl-1. (B)Quantitation of immunoblots for each cell line was performed by 
measuring ratios of Mcl-1 to GAPDH for each SGI-1776 treatment, and normalized to DMSO 
control. Experiments were performed in triplicate and results were shown as average ratios ± SEM.  
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Results indicated a dose-dependent decrease of Mcl-1/GAPDH in both cell lines following 
SGI-1776 treatment at concentrations greater than 3μM in both cell lines. Again, of the two cell lines, 
there was a more dramatic decrease of Mcl-1 levels in JeKo-1 compared to Mino.  
JeKo-1 and Mino cells were also treated with 10μM of SGI-1776 for increasing times, and 
Mcl-1 and GAPDH protein expression levels were detected (Figure 20A), and ratios of Mcl-
1/GAPDH were normalized to DMSO control (Figure 20B). Notably, only JeKo-1 cells, there was a 
clear time-dependent decrease of Mcl-1 expression, whereas in Mino, although moderate decrease 
(up to 25%) was observed by 2hr, there is an increase of Mcl-1 level at 4hr followed by further 
decrease of this protein.   
Effect of SGI-1776 on other anti-apoptotic proteins in MCL cell lines.  
Due to lack of consistent decrease of cell-death-inducing phospho-Bad levels in MCL cell 
lines, and the limited degree of inhibition of both Mcl-1 mRNA and protein levels, we hypothesize 
that anti-apoptosis proteins other than Mcl-1 may play a role in apoptosis induction in MCL. We 
investigated the effect of SGI-1776 in other Bcl-2 family proteins (Bcl-2, Bcl-XL) and XIAP, which 
are all anti-apoptosis proteins known to play a role in NHL (Akyurek 2006; Perez-Galan 2011).  
JeKo-1 and Mino cells were treated with SGI-1776 for different doses for 24hr, and cells 
were harvested for immunoblot analysis (Figure 21A, B). Interestingly, we did not see any decrease 
of these protein expression levels in either cell line. In JeKo-1, only 10μM treatment of SGI-1776 
lead to decrease of Bcl-XL and XIAP levels, and this could be due to the extensive cell death as 
shown by the decrease of GAPDH protein levels.   
Aim 2.4. Effect of SGI-1776 on cell cycle profile and cell cycle regulators in MCL cell lines.  
Effect of SGI-1776 on cell cycle profiles in MCL cell lines. 
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Figure 20. Time-dependent reduction of Mcl-1 protein expression levels by SGI-1776 treatment 
in MCL cell lines.  
(A)MCL cell lines JeKo-1, Mino cells were treated with DMSO or with 10µM of SGI-1776 for 
different time points (0.5, 1, 2, 4, 8, 16 and 24hr). Protein lysates were analyzed using immunoblot to 
detect the expression levels of Mcl-1. (B)Quantitation of immunoblots for each cell line was 
performed by acquiring ratios of Mcl-1 to GAPDH for each SGI-1776 treatment, and then ratios 
from each treatment were normalized to the result of DMSO-treated experiment. Experiments were 
performed in triplicate and results were shown as average ratios ± SEM.  
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Figure 21. Effect on other Bcl-2 family proteins and XIAP by SGI-1776 treatment in MCL cell 
lines.  
MCL cell lines (A)JeKo-1 and (B)Mino cells were treated with DMSO or with 10µM of SGI-1776 
for different time points (0.5, 1, 2, 4, 8, 16 and 24hr). Protein lysates were analyzed using 
immunoblot to detect the expression levels of Bcl-2 family proteins Bcl-2, Bcl-XL and XIAP. 
Experiments were performed in duplicate.  
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Pim kinases are known to regulate cell cycle regulators such as p27 and cdc25C (Chen 2010), 
therefore, we hypothesize that cell cycle profile would be affected by SGI-1776 treatment. We 
treated JeKo-1 and Mino cells with different doses of SGI-1776 for 24hr, and then cells cycle 
profiles were measured and analyzed using flow cytometry; percentages of cells in each cell cycle 
phase were measured (Figure 22).  
In JeKo-1 cells, little change was observed in cell cycle profile, and with 10μM SGI-1776, 
there was only a slight increase of G1-staged cells compared to DMSO-treated cells (<5%, Figure 
22A). However, in Mino cells, there was a clear dose-dependent increase of G1 population 
accompanied with decrease of S and G1 population compared to DMSO control, with 3%, 12% and 
37% increase in G1-phased cells in 3, 5 and 10μM SGI-1776, respectively (Figure 22B).  
Effect of SGI-1776 on cdc25C phosphorylation in MCL cell lines.  
To further investigate Pim kinases’ role in cell cycle regulation, we analyzed the changes of 
phosphorylation levels of a known Pim kinase substrate, cdc25C (Bachmann 2006).  
As mentioned above, JeKo-1 and Mino cells were treated with SGI-1776 for 24hr and then 
cells were harvested for immunoblot analysis of phospho- and total cdc25C protein expression levels 
(Figure 23).  
Although in JeKo-1 cells, phospho-cdc25C (Ser216) levels decreased with increasing SGI-
1776, there was an even more significant dose-dependent decrease of total cdc25C levels, making it 
difficult to draw a conclusion for changes of phospho-cdc25C levels. In Mino cells, neither phospho- 
nor total protein levels decreased, also suggesting an inconclusive result.  
Effect of SGI-1776 on cyclin D1 levels in MCL cell lines. 
  
67 
 
Figure 22. Cell line-specific differential effect on cell cycle by SGI-1776 treatment in MCL cell 
lines.  
MCL cell lines (A)JeKo-1 and (B)Mino cells were treated with DMSO or with different doses of 
SGI-1776 (0.1, 1, 3, 5, 10µM) for 24hr, then cells were fixed with ice cold 70% ethanol and then 
incubated with propidium iodine. Cell cycle profiles were analyzed using flow cytometry, where G1, 
S, G2/M cell cycle stages were shown as percent population. Experiments were performed in 
triplicate and results were shown as average percentages ± SEM.  
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Cyclin D1 is a cell cycle regulator protein with oncogenic feature when overexpressed due to 
t(11;14) (q13;q32), it is also the molecular hallmark of MCL disease (Vasef 1997).  It has been 
shown that MCL cell lines JeKo-1 and Mino are cyclin D1 positive (Amin 2003). Pim kinases are 
reportedly known to regulate cell cycle proteins, but their relationship with cyclin D1 is unknown 
(Mochizuki 1999). Therefore, we hypothesize that cyclin D1 level would be affected by SGI-1776, 
and carried out immunoblot analysis to test this hypothesis.     
JeKo-1 and Mino cells were treated with SGI-1776 in various doses for 24hr and 10μM dose 
for different time points, then cells were harvested, and protein lysates were extracted for 
immunoblot analysis (Figure 24A, B). In JeKo-1 cells, there was a clear decrease of cyclin D1 in 
both dose- and time-dependent fashions. Notably, significant decrease of cyclin D1 was detected at 
3μM or higher concentrations of SGI-1776 for 24hr, or 4hr or longer for 10μM SGI-1776 treatments. 
However, in Mino cells, we observed dose- and time-dependent increase of cyclin D1 levels with 
SGI-1776 treatments, which was in contract with the results in JeKo-1. 
Aim 2.5. Effects of PIM1, PIM2 and PIM1/2 siRNAs in MCL cell lines.  
To confirm the findings of SGI-1776 on Pim kinase phosphorylation substrates and Mcl-1 
mRNA and protein levels are on-target effects, we conducted siRNA knockdown studies using single 
siRNAs PIM1, PIM2, and combination of PIM1 and PIM2 (denoted as PIM1/2) in MCL cell lines 
JeKo-1 and Mino, and performed immunoblots, RT-PCR experiments to evaluate the changes of Pim 
kinase substrate phosphorylation levels and Mcl-1 protein and mRNA levels. 
Effects of PIM1, PIM2, and PIM1/2 siRNA on PIM1, PIM2 and MCL1 mRNA levels.  
JeKo-1 and Mino cells were transfected with PIM1, PIM2, and PIM1/2 siRNA using 
electrophoresis method, and then cells were placed back in cell culture and harvested after 24hr. 
Total RNA was extracted for RT-PCR experiment to detected PIM1 and PIM2 and MCL1 mRNA 
levels (Figure 25).   
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Figure 24. Cell line-specific differential effect on cyclin D1 by SGI-1776 treatment in MCL cell 
lines.  
MCL cell lines (A)JeKo-1 and (B)Mino cells were treated with DMSO or with different doses of 
SGI-1776 (0.1, 1, 3, 5, 10µM) for 24hr, or with 10µM of SGI-1776 for different time points (0.5, 1, 
2, 4, 8, 16 and 24hr). Protein lysates were extracted from the cells and then analyzed using 
immunoblot to detect the expression levels of cyclin D1 protein. Experiments were performed twice.  
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Figure 25. Effect on PIM1, PIM2 and MCL1 mRNA expression levels by PIM1, PIM2 siRNA 
treatments in MCL cell lines.  
(A)JeKo-1 and (B)Mino cells were transfected with 150nM of scramble siRNA, transfection 
indicator siGLO, either PIM1 or PIM2 siRNA alone or with combination of PIM1 and PIM2 siRNA 
using electroporation method. After 24hr post-transfection incubation, cell viability and transfection 
efficiency were tested using flow cytometry, and cells were harvested for RT-PCR study. Short-lived 
PIM1, PIM2 and MCL1 mRNA expression levels were detected and results were normalized to 
scramble control. Experiments were performed in triplicate and results were shown as average ratios 
± SEM. 
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In JeKo-1 cells, PIM1 siRNA lead to significant decrease of PIM1 mRNA expression 
(>60%), but much smaller effect was observed on MCL1 mRNA level (~20%) and even less for 
PIM2 mRNA (~10%). Meanwhile, PIM2 siRNA treatment equally reduced both PIM1 and PIM2 
mRNA levels to around 60% of scramble control, while reducing MCL1 mRNA level by 30%. For 
PIM1/2 knockouts, reduction of PIM1 and PIM2 mRNA levels were compatible to those of PIM1 or 
PIM2 single knockouts, however, MCL1 mRNA level was reduced much more than PIM1, PIM2 
single knockouts, reaching more than 60% reduction, which is more than PIM1 and PIM2 single 
knockouts combined (Figure 25A).  
In Mino cells, similar trends were observed (Figure 25B). PIM1 single knockout lead to 50%, 
10% and 30% reduction in PIM1, PIM2 and MCL1 mRNA levels, respectively. Meanwhile, PIM2 
single knockout caused 14%, 70% and 30% reduction of PIM1, PIM2 and MCL1 levels. PIM1/2 
double knockout resulted in 50% reduction in PIM1, which is comparable to single PIM1 knockout. 
However, less reduction in PIM2 was observed (43%) compared to PIM2 single knockout which was 
70% reduction. We also observed synergistic effect in decreasing MCL1 in PIM1/2 double knockout 
study, which was a robust 72% decrease, compared to 30% in both PIM1and PIM2 single knockout 
studies.  
Effect of PIM1, PIM2, PIM1/2 siRNA on Mcl-1 protein levels in JeKo-1.  
Based on the results of PIM1, PIM2 and PIM1/2 siRNA knockouts on MCL1 mRNA, we 
hypothesized that similar results will be observed in Mcl-1 protein in JeKo-1. JeKo-1 cells were 
treated with PIM1, PIM2 and PIM1/2 siRNAs, and then cells were harvested and protein lysates 
were used to perform immunoblots (Figure 26A). Mcl-1 and GAPDH proteins were detected and 
quantitated; Mcl-1/GAPDH levels were calculated and normalized to scramble control (Figure 26B).   
As shown in Figure 26B, PIM1/2 double knockout lead to the most amount of decrease in 
MCL1 compared to the single knockouts, and PIM2 knockout was more effective in reducing MCL1  
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Figure 26. Effect on Mcl-1 protein expression levels by PIM1, PIM2 siRNA treatments in JeKo-
1 cells. 
(A)JeKo-1 cells were transfected with 150nM of scramble siRNA, transfection indicator siGLO, 
either PIM1 or PIM2 siRNA alone or with combination of PIM1 and PIM2 siRNA using 
electroporation method. After 24hr post-transfection incubation, cell viability and transfection rate 
were tested using flow cytometry, and cells were harvested for immunoblot study. Levels of Mcl-1 
and GAPDH protein expression were measured. (B)Quantitation of the immunoblot with siRNA-
treated JeKo-1 cells. Mcl-1 to GAPDH ratios were calculated and results were normalized to 
scramble control. Annexin V/PI positivity values indicating apoptosis level were marked under each 
lane of western blot. All experiments were performed in triplicate and results were shown as average 
ratios ± SEM. 
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than PIM1 knockout. However, for each siRNA treatment, the reduction of MCL mRNA was less 
extensive compared to their equivalent mRNA level.  
Effect of PIM1, PIM2, PIM1/2 siRNA on Mcl-1 protein levels in Mino.  
Mino cells were also treated with PIM1, PIM2 and PIM1/2 siRNA and their effect on Mcl-1 
protein levels were measured (Figure 27). It appears that PIM1 single knockout did not result in a 
decrease of Mcl-1level in Mino. However, PIM2 single knockout and PIM1/2 double knockout lead 
to reduction of Mcl-1 levels by 5%, and 16%, respectively.   
Effects of PIM1, PIM2 and PIM1/2 siRNA on Pim kinase phosphorylation targets in JeKo-1. 
c-Myc and 4E-BP1 phosphorylation was consistently decreased in SGI-1776-treated JeKo-1 
and Mino cells, therefore, we investigated whether the effect on these Pim kinase phospho-targets 
are consistent with PIM1, PIM2 and PIM1/2 siRNA-treated cells. Both JeKo-1 and Mino cell lines 
were treated with these siRNAs, and then cells were harvested and protein lysates were extracted for 
immunoblot analysis. Both phospho- and total c-Myc and 4E-BP1 were detected and quantitated 
(Figure 28A), and ratios of phospho- to total protein levels were calculated, normalized to scramble 
control, and then plotted (Figure 28B).  
In JeKo-1 cells, PIM1 single knockout lead to a decrease in both phospho-c-Myc and 4E-
BP1 at 20% compared to control, however, PIM2 single knockout neither reduced phospho-c-Myc 
by 5% nor phospho-4E-BP1 levels. PIM1/2 double knockout caused around 20% reduction of both 
phospho-c-Myc and 4E-BP1, compatible to that of PIM1 single knockout.  
Effects of PIM1, PIM2 and PIM1/2 siRNA on Pim kinase phosphorylation targets in Mino. 
 Mino cells were also treated with PIM1, PIM2 and PIM1/2 siRNAs, and immunoblots of 
phospho- and total c-Myc and 4E-BP1 were measured and quantitated (Figure 29A). Plotted ratios of 
phospho- to total protein levels indicated that phospho-c-Myc levels were decreased in all three  
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Figure 27. Effect on Mcl-1 protein expression levels by PIM1, PIM2 siRNA treatments in Mino 
cells. 
(A)Mino cells were transfected with 150nM of scramble siRNA, transfection indicator siGLO, either 
PIM1 or PIM2 siRNA alone or with combination of PIM1 and PIM2 siRNA using electroporation 
method. After 24hr post-transfection incubation, cell viability and transfection rate were tested using 
flow cytometry, and cells were harvested for immunoblot study. Levels Mcl-1 and GAPDH protein 
expression were measured. (B)Quantitation of the immunoblot with siRNA-treated Mino cells. Mcl-
1 to GAPDH ratios were calculated and results were normalized to scramble control. Annexin V/PI 
positivity values indicating apoptosis levels were marked under each lane of western blot. All 
experiments were performed in triplicate and results were shown as average ratios ± SEM. 
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Figure 28. Effect on Pim kinase phosphorylation targets by PIM1, PIM2 siRNA treatments in 
JeKo-1 cells. 
(A)JeKo-1 cells were transfected with 150nM of scramble siRNA, transfection indicator siGLO, 
either PIM1 or PIM2 siRNA alone or with combination of PIM1 and PIM2 siRNA using 
electroporation method. After 24hr post-transfection incubation, cell viability and transfection rate 
were tested using flow cytometry, and cells were harvested for immunoblot study. Levels of 
phospho-c-Myc (Ser62), total c-Myc, phospho-4E-BP1 (Thr37/46), total 4E-BP1, and GAPDH 
protein expression were measured. (B)Quantitation of the immunoblot with siRNA-treated JeKo-1 
cells. Ratios of phospho- to total proteins were calculated and results were normalized to scramble 
control. Annexin V/PI positivity values indicating apoptosis level were marked under each lane of 
western blot. All experiments were performed in triplicate and results were shown as average ratios 
± SEM. 
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Figure 29. Effect on Pim kinase phosphorylation targets by PIM1, PIM2 siRNA treatments in 
Mino cells. 
(A)Mino cells were transfected with 150nM of scramble siRNA, transfection indicator siGLO, either 
PIM1 or PIM2 siRNA alone or with combination of PIM1 and PIM2 siRNA using electroporation 
method. After 24hr post-transfection incubation, cell viability and transfection rate were tested using 
flow cytometry, and cells were harvested for immunoblot study. Levels of phospho-c-Myc (Ser62), 
total c-Myc, phospho-4E-BP1 (Thr37/46), total 4E-BP1, and GAPDH protein expression were 
measured. (B)Quantitation of the immunoblot with siRNA-treated Mino cells. Ratios of phospho- to 
total proteins were calculated and results were normalized to scramble control. Annexin V/PI 
positivity values indicating apoptosis levels were marked under each lane of western blot. All 
experiments were performed in triplicate and results were shown as average ratios ± SEM. 
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siRNA treatment conditions, with 20%, 25% and 35% decrease in PIM1, PIM2 and PIM1/2 siRNA- 
treated cells, respectively (Figure 29B). However, only slight decrease (~10%) decrease in phoshpo-
4E-BP1 level was observed in PIM1/2 double knockout studies but not the single knockout studies.  
Aim 2.6. Effect of SGI-1776 on MCL primary samples.  
To determine if SGI-1776’s effect of reducing phospho-c-Myc (Ser62) and phospho-4E-BP1 
(Thr37/46) levels in MCL cell lines is also observed in MCL primary cells, we investigated the 
effects of this drug on Pim kinase phosphorylation targets and oncoprotein Mcl-1 and cyclin D1 
using malignant PBMCs isolated from MCL primary patient samples (Table 3).   
Effect of SGI-1776 on Pim kinase phosphorylation targets in MCL primary samples.  
PBMCs were isolated from late-staged MCL patients, and the SGI-1776 treatment was 
started on the same day of isolation (Table 2). Primary MCL cells were treated with increasing doses 
of SGI-1776 (0.1, 1, 3, 5, 10μM) for 24hr and then cells were harvested for flow cytometry and 
immunoblot analyses (Figure 30).  
Phospho- and total c-Myc and 4E-BP1 protein levels were evaluated, and for both phospho-
c-Myc and phospho-4E-BP1, there was a dose-dependent decrease with the SGI-1776 treatment. In 
addition, there was also a dose-dependent increase of apoptosis (n=3), with about 30% increase in 
cell death was observed by 10μM SGI-1776 among all samples.  
Effect of SGI-1776 on Mcl-1 and cyclin D1 levels in MCL primary patent samples. 
 We then tested the effect of SGI-1776 on short-lived oncoproteins cyclin D1 and 
Mcl-1 in MCL primary samples; as both are known to be over expressed in MCL patients and play a 
role in worsen patient prognosis and treatment outcomes (Vasef 1997; Khoury 2003). 
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Table  3.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. MCL patient characteristics. 
 
§Samples 2 and 3 are from the sample patient but obtained on different days.  
*This patient had stage IV disease but was in remission when the blood samples were collected. 
Therefore, these samples served as normal PBMCs. 
AS, apheresis sample; PB, peripheral blood.  
 
 
  
Patient numbers 1 §2 §3 *4 5 
Dx MCL MCL MCL MCL MCL 
Sample type AS PB PB PB AS 
Tumor cells % of 
lymphocytes 90 80 80 0 0 
Patient age, yrs 74 54 54 53 75 
White blood count, per µL 213,000 79,000 53,000 58,000 67,700 
Lymphocytes% 99 75 77 1 94 
Neutrophils% 1 21 22 86 6 
Metaphase% 0 0 0 0 7 
Blasts% 0 0 0 1 0 
Monocytes% 0 4 1 1 0 
Growth Factor No No No Neopogen No 
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Figure 30. Dose-dependent reduction of Pim kinase phosphorylation targets by SGI-1776 
treatment in primary MCL patient samples. 
(A)Malignant PBMCs isolated from blood samples of MCL patients were either untreated, or treated 
with DMSO or different doses of SGI-1776 (0.1, 1, 3, 5, 10µM) for 24hr. Then cells were harvested 
and viability of cells with or without SGI-1776 treatment was tested using flow cytometry. Protein 
lysates were extracted and immunoblots were performed to analyze changes of phospho-c-Myc 
(Ser62), 4E-BP1 (Th37/46). Expression levels of phospho-c-Myc (Ser62) and total c-Myc, phospho-
4E-BP1 (Thr37/46) and total 4E-BP1 as well as GAPDH protein expression were measured. 
Annexin V/PI positivity values were marked under each lane of immunoblot.   
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Patient samples were treated with various doses of SGI-1776 for 24hr, then cells were 
harvested and analyzed for their Mcl-1 and cyclin D1 protein expression levels by immunoblots 
(Figure 31). In the three MCL patient samples, both Mcl-1 and cyclin D1 were detected by 
immunoblots and SGI-1776 treatment lead to a dose-dependent decrease of both proteins, that at 
3μM or higher doses, the levels of expression almost diminished for all three samples.  
Effect of SGI-1776 on Pim kinase phosphorylation targets in normal PBMCs. 
 There should be a good therapeutic window for anti-cancer drugs in clinical use, which 
requires the drug to be specifically cytotoxic towards malignant cancer cells but not healthy cells in 
patients.  
To compare the effect of SGI-1776 in normal PBMCs, we obtained PBMCs from three 
healthy donors and a MCL patient who is in remission, indicated by the very low levels of 
lymphocyte count (Table 2).  Normal PBMCs were treated with SGI-1776 for 24hr with different 
doses (1, 3 and 10μM), and then Pim kinase phosphorylation targets c-Myc and 4E-BP1 were 
evaluated using immunoblots (Figure 32). 
Notably, cells from the patient in remission (MCL#4) expressed a higher level of phospho- 
and total c-Myc levels compared to the healthy donors, but all four samples showed much lower 
expression levels of phospho- and total c-Myc and 4E-BP1 compared to the positive control, 
untreated Mino cells. Importantly, there was no obvious trend of decrease in phosphorylation levels 
of c-Myc or 4E-BP1 in any of these samples. In addition, in all four samples tested, apoptosis levels 
were very low compared to the malignant samples tested, even high SGI-1776 doses did not kill the 
cells.  
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Figure 31. Dose-dependent reduction of short-lived Mcl-1 and cyclin D1 protein expression 
levels by SGI-1776 treatment in primary MCL patient samples. 
(A)Malignant PBMCs isolated from blood samples of MCL patients were either untreated, or treated 
with DMSO or different doses of SGI-1776 (0.1, 1, 3, 5, 10µM) for 24hr. Then cells were harvested 
and viability of cells with or without SGI-1776 treatment was tested using flow cytometry. Protein 
lysates were extracted and immunoblots were performed to analyze changes of short-lived 
oncoproteins Mcl-1 and cyclin D1 levels. Expression levels of Mcl-1, cyclin D1 and GAPDH protein 
expression were measured. Annexin V/PI positivity values indicating apoptosis levels were marked 
under each lane of western blot.   
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Figure 32. Effect on Pim kinase phosphorylation targets by SGI-1776 treatment in normal 
PBMCs. 
Normal PBMCs isolated from a patient in remission, and three healthy donors’ blood samples were 
either untreated or treated with DMSO or different doses of SGI-1776 (1, 3, 10µM) for 24hr. Cells 
were harvested and protein lysate was extracted for immunoblot analysis. Expression levels of 
phospho- and total c-Myc, phospho- and total 4E-BP1, and GAPDH proteins were measured. 
Annexin V/PI positivity values were marked under each lane of the immunoblots. Untreated Mino 
cells were used as positive control displayed on the far right panel.  
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Effect of SGI-1776 on MCl-1 and cyclin D1 levels in normal PBMCs. 
We also tested the effect of SGI-1776 on Mcl-1 and cyclin D1 in normal PBMCs, and found 
that although some normal PBMCs express high levels of Mcl-1, but SGI-1776 failed to reduce their 
levels even at high doses (Figure 33).    
Effect of SGI-1776 on MCL1 mRNA levels in MCL primary patent samples. 
 To further validate the effect of SGI-1776 on transcription regulation, we tested its effect on 
short-lived MCL1 mRNA levels, in malignant PBMCs (Figure 34). Two late-staged MCL samples 
were used to isolate malignant PBMCs for this study. Cells were treated with DMSO, or 1, 3, and 
5μM of SGI-1776 for 24hr, then they were harvested and total RNA was extracted for RT-PCR 
studies.  
In both samples, there was a dose-dependent decrease of MCL1 mRNA levels, started at 
1μM concentration. MCL#1 had a greater than 40% decrease of MCL1 by 10μM whereas in MCL#5, 
this level dropped to 44% of DMSO control.  
Effect of SGI-1776 on MCL1 mRNA levels in normal PBMCs. 
 We also tested the effect of SGI-1776 on MCL1 levels in normal PBMCs, where cells were 
also treated with SGI-1776 (1, 3, 10μM) for 24hr as mentioned above (Figure 35).  
Interestingly, we did not observe a consistent trend of decrease of MCL1 levels in these 
samples ‒in MCL#4, MCL1 level first increased and then dropped to 80% of DMSO control, 
whereas in Lymph# 2 and 3, the MCL1 levels decreased by 3μM but increased at 10μM.  
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Figure 33. Dose-dependent reduction of short-lived Mcl-1 and cyclin D1 protein expression 
levels by SGI-1776 treatment in normal PBMCs. 
Normal PBMCs isolated from a patient in remission, and three healthy donors’ blood samples were 
either untreated or treated with DMSO or different doses of SGI-1776 (1, 3, 10µM) for 24hr. Cells 
were harvested and protein lysate was extracted for immunoblot analysis. Expression levels of Mcl-1, 
cyclin D1 and GAPDH proteins were measured. Annexin V/PI positivity values were marked under 
each lane of the immunoblots. Untreated Mino cells were used as positive control displayed on the 
far right panel.    
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Figure 34. Reduction of MCL1 mRNA levels in MCL primary cells.  
Malignant PBMCs isolated from two blood samples of MCL patients were either untreated or treated 
with DMSO or different doses of SGI-1776 (1, 3, 10µM) for 24hr. Cells were then harvested and 
total RNA was extracted and purified. Expression levels of MCL1 mRNA were measured using RT-
PCR, and results were normalized to 18S and also DMSO control.  
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Figure 35. Effect on MCL1 mRNA levels by SGI-1776 treatment in normal PBMCs.  
Normal PBMCs isolated from a patient in remission, and three healthy donors’ blood samples of 
were either untreated or treated with DMSO or different doses of SGI-1776 (1, 3, 10µM) for 24hr. 
Cells were then harvested and total RNA was extracted and purified. Expression levels of MCL1 
mRNA were measured using RT-PCR, and results were normalized to 18S and DMSO control.  
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Aim 2.7. Relationships among events of transcription, translation and cell death in MCL cell lines.   
In order to generate a clear picture among the relationships among the phenomenon observed 
on transcription, translation and cell death lead by SGI-1776 treatments in MCL cell lines, we drew 
correlations between specific events of each aspect.  
Relationship between global transcription inhibition and cell death in MCL cell lines.  
First, we began by evaluating the relationship between global transcription reduction and cell 
death. To establish the relationship, we chose the global RNA synthesis inhibition data of the dose-
dependent SGI-1776 treatment in four MCL cell lines, calculated into percentages of total population 
and normalized to DMSO control, and then plotted them against cell death data, also in percentage 
and normalized to control (Figure 36). 
Linear correlation was drawn and the calculated linear regression values were >0.9 for JeKo-
1, Granta 519 and Mino, whereas in SP-53, r2 =0.68. Collectively of the four cell lines together, 
r2=0.8 with p<0.0001. This indicated that RNA synthesis inhibition was directly correlated with cell 
death in four MCL cell lines.   
Relationship between reduction of c-Myc (Ser62) phosphorylation and inhibition of global 
transcription in MCL cell lines.  
We tested the relationship between reduction of c-Myc (Ser62) phosphorylation ‒a 
consistent event triggered by SGI-1776 treatment in both MCL cell lines and MCL primary samples, 
and global RNA synthesis in JeKo-1 and Mino cell lines. Ratios of c-Myc (Ser62)/total c-Myc were 
calculated from dose-dependent SGI-1776 treatments in both cell lines, normalized to DMSO control, 
and then plotted against global transcription inhibition (Figure 37).  
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Figure 36. Strong correlation between global RNA synthesis inhibition and cell death lead by 
SGI-1776 treatment in MCL cell lines. 
Both global RNA synthesis and cell death was measured in percentage of population, values were 
taken from dose-dependent SGI-1776 treatment for 24hr in JeKo-1, Mino, Granta 519 and SP-53 
MCL cell lines. RNA synthesis inhibition was correlated with cell death by using linear regression, 
and r2 and p values were calculated using the GraphPad Prism software.  
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Figure 37. Strong correlation between decrease of c-Myc phosphorylation and RNA synthesis 
inhibition lead by SGI-1776 treatment in MCL cell lines. 
Both decrease of c-Myc phosphorylation and cell death was measured in percentage of population, 
whereas ratios of phospho-c-Myc to total c-Myc was calculated then normalized to DMSO control. 
Values were taken from dose-dependent SGI-1776 treatment for 24hr in JeKo-1 and Mino cell lines. 
Phospho-c-Myc/total c-Myc was correlated with RNA synthesis inhibition using linear regression, 
and r2 and p values were calculated using the GraphPad Prism software.  
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We observed a strong correlation between decrease of c-Myc phosphorylation and cell death 
in both cell lines, with linear regression value of >0.9, and p<0.02, suggesting the direct relationship 
of these two events. 
Relationship between reduction of c-Myc (Ser62) phosphorylation and decrease of MCL1 
mRNA levels in MCL cell lines.  
 We tested the relationship within transcription regulation, between decrease of c-Myc 
phosphorylation and reduction of MCL1 mRNA levels in JeKo-1 and Mino cells treated with SGI-
1776. Data were extracted from immunoblots evaluating c-Myc phosphorylation and RT-PCR 
measuring changes of MCL1 levels, calculated into c-Myc (Ser62)/total c-Myc and MCL1/18s, 
respectively, both normalized to DMSO control, and then plotted against each other (Figure 38).  
 We were also able to draw a strong association between the two events, with r2=0.7 and 
p<0.03 with two cell lines taken together, which indicate a direct relationship of the two events.  
Relationship between reduction of 4E-BP1 (Thr37/46) and cell death in MCL cell lines. 
 We also evaluated the relationship between translation and cell death, by drawing 
association between reduction of 4E-BP1 (Thr37/46) and increase in apoptosis levels in JeKo-1 and 
Mino cells treated with SGI-1776. Data were taken from immunoblots measuring the changes of 
phosphorylation of 4E-BP1 in dose-dependent SGI-1776 treatments in JeKo-1 and Mino cells, and 
ratios of phospho-/total protein levels were calculated, and plotted against apoptosis levels (Figure 
39). Linear regression was performed and r2 and p values were calculated using the GraphPad Prism 
software. 
  
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Strong correlation between decrease of c-Myc phosphorylation and decrease of 
MCL1 mRNA levels by SGI-1776 treatment in MCL cell lines. 
Both decrease of c-Myc phosphorylation and decrease in MCL1 mRNA levels were measured in 
percentage of population, whereas ratios of phospho-c-Myc to total c-Myc was calculated then 
normalized to DMSO control, also ratios of MCL1 to 18S was calculated and also normalized to 
DMSO control. Values were taken from dose-dependent SGI-1776 treatment for 24hr in JeKo-1 and 
Mino cell lines. Phospho-c-Myc/total c-Myc was correlated with reduction of MCL1 levels using 
linear regression, and r2 and p values were calculated using the GraphPad Prism software. 
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Figure 39. Strong correlation between decrease of 4E-BP1 phosphorylation and cell death by 
SGI-1776 treatment in MCL cell lines.  
Both decrease of 4E-BP1 phosphorylation and cell death levels were measured in percentage of 
population, whereas ratios of phospho-4E-BP1 to total 4E-BP1 was calculated then normalized to 
DMSO, cell death levels were also normalized to DMSO control. Values were taken from dose-
dependent SGI-1776 treatment for 24hr in JeKo-1 and Mino cell lines. Phospho-4E-BP1/total 4E-
BP1 was correlated with cell death levels using linear regression, and r2 and p values were calculated 
using the GraphPad Prism software. 
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As expected, a strong correlation was detected between decrease of phospho-4E-BP1 and 
increase of apoptosis, with linear regression value of >0.9 and p<0.01. This also points to a direct 
relationship between translation inhibition and cell death.  
Relationship between reduction of 4E-BP1 (Thr37/46) and Mcl-1 protein levels in MCL cell 
lines.  
With regard to translation regulation, we looked at decrease of phospho-4E-BP1 and Mcl-1 
protein levels in SGI-1776-treated JeKo-1 and Mino cells (Figure 40). Again, we found strong 
association between decrease of 4E-BP1 phosphorylation and Mcl-1 protein, with r2>0.9 and 
p<0.004. 
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Figure 40. Strong correlation between decrease of 4E-BP1 phosphorylation and decrease of 
MCL1 mRNA levels by SGI-1776 treatment in MCL cell lines. 
Both decrease of 4E-BP1 phosphorylation and decrease in MCL1 mRNA levels were measured in 
percentage of population, whereas ratios of phospho-4E-BP1 to total 4E-BP1 was calculated then 
normalized to DMSO, also ratios of MCL1 to 18S was calculated and also normalized to DMSO 
control. Phospho-4E-BP1/total 4E-BP1 was correlated with reduction of Mcl-1 levels using linear 
regression, and r2 and p values were calculated using the GraphPad Prism software. 
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CHAPTER 4. Combination of bendamustine with SGI-1776 in B-cell lymphoma 
Bendamustine is as an FDA-approved drug for NHL that disrupts DNA replication and 
transcription processes by inducing DNA damage in both replicating and quiescent cells (Leoni 2008; 
Gandhi 2009). Our studies in MCL have demonstrated that SGI-1776 is cytotoxic in MCL, and its 
primary mechanism of actions is through targeting transcription and translation, which leads to cell 
death.  Based on the mechanism of actions of bendamustine and SGI-1776, we hypothesized that 
combination of bendamustine with SGI-1776 will enhance bendamustine-triggered DNA synthesis 
disruption, while promoting SGI-1776-induced transcription and translation inhibition, which will 
subsequently lead to more efficient growth inhibition and cell killing in B-cell lymphoma (Figure 41). 
We also hypothesized that such combination will result in additive to synergistic cytotoxicity in 
lymphoma cells, and propose the following aim.  
Aim 3) Explore the combination strategy of SGI-1776 with bendamustine to identify the 
primary mechanism of actions to induce cytotoxicity in B-cell lymphoma.   
To test this hypothesis, we used 5 and 10μM of bendamustine as this is easily achieved in 
plasma at maximum tolerated dose. Concentration of SGI-1776 (5μM) was selected based on single 
agent data in MCL cells described in Chapter 3.  
Aim 3. Explore the combination strategy of SGI-1776 with bendamustine to identify the 
primary mechanism of actions to induce cytotoxicity in B-cell lymphoma. 
Aim 3.1. Effect on apoptosis induction by bendamustine and SGI-1776 combination treatment in B-
cell lymphoma cells.  
 Effect on apoptosis induction by bendamustine and SGI-1776 combination treatment in 
MCL cell lines.  
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Figure 41. Rationale for combination strategy of bendamustine with SGI-1776 in MCL.  
SGI-1776 has shown to sequester transcription and translation pathways whereas bendamustine 
inhibits DNA synthesis and transcription. Therefore, we hypothesize that combination of these two 
agents will lead to additive effect in causing apoptosis and disrupting cell proliferation processes.  
Figure	41.		
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MCL cell lines JeKo-1 and Mino were treated with DMSO, or selected concentrations of 
bendamustine (5, 10μM) and SGI-1776 (5μM), or combination of the two drugs (5μM of 
bendamustine +5μM SGI-1776, or 10μM bendamustine +5μM SGI-1776) for 24hr. Then cells were 
harvested and analyzed using flow cytometry for annexin V/PI positivity to measure induced 
apoptosis levels (Figure 42).  
In JeKo-1 cells, an increase of 10% and 18% of apoptosis was measured in 5 and 10μM of 
bendamustine-treated cells, whereas 5μM SGI-1776 resulted in 13% cell death. In combination 
treatments, 5 or 10μM bendamustine +5μM SGI-1776 killed 24% and 34% of cells, respectively 
(Figure 42A). Using fractional analysis, the combination method showed more than additive to 
synergistic effect in cytotoxicity (Table 4).  
 In Mino cells, an increase of 10% and 22% of apoptosis was observed in 5 and 10μM of 
bendamustine treatments, while 5μM SGI-1776 killed 10% of the cells. Apoptosis levels in 
combination treatments were 15% and 25% for 5 or 10μM bendamustine +5μM SGI-1776, 
respectively (Figure 42B). Fractional analysis indicated more than additive effect in apoptosis 
induced by bendamustine and SGI-1776 combination in Mino cells (Table 4).  
Effect in cell killing induced by bendamustine and SGI-1776 combination treatment in B-
cell lymphoma primary samples.  
 To investigate the effect of bendamustine and SGI-1776 combination treatment in primary 
cells, we isolated malignant PBMCs from primary samples from patients diagnosed with MCL and 
splenic marginal zone lymphoma, also a B-cell lymphoma (Table 5). As with the cell lines, primary 
cells were treated with single agent SGI-1776 or bendamustine alone, or combination of the two 
drugs for 24hr, and apoptosis levels were analyzed using flow cytometry (Figure 43).  
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Figure 42. Cell death induced by bendamustine and SGI-1776 combination treatment in MCL 
cell lines.  
MCL cell lines (A)JeKo-1 and (B)Mino were treated with DMSO, or different doses of 
bendamustine (5, 10µM) or 5µM SGI-1776, or combination of these two drugs are these 
concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, then apoptosis levels were 
measured by annexin V/PI positivity measured by flow cytometry. Experiments were done in 
triplicate and results were shown as average cell death levels ± SEM.  
B, bendamustine; S, SGI-1776.  
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Table  4.  
 
 Expected cell death Observed cell death 
5µM Bendamustine
+5µM SGI-1776 
10µM Bendamustine
+5µM SGI-1776 
5µM Bendamustine 
+5µM SGI-1776 
10µM Bendamustine
+5µM SGI-1776 
JeKo-1 10% 18% 18% 28% 
Mino 9% 26% 13% 31% 
MCL 23% 24% 18% 21% 
SMZL 34% 38% 35% 37% 
 
 
 
Table 4. Factional analysis of combination of SGI-1776 with bendamustine in B-cell lymphoma. 
Formula for fractional analysis:  
%survival drug A X %survival drug B=Expected survival 
1-%Expected survival rate=%Expected death 
 Expected death>Observed death Less than additive to antagonistic 
 Expected death=Observed death Additive 
 Expected death<Observed death More than additive to synergistic 
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Table  5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. B-cell lymphoma patient characteristics. 
 
SMZL: splenic marginal zone lymphoma 
PB, peripheral blood.  
 
 
  
Patient numbers 6 7 
Dx MCL SMZL 
Sample type PB PB 
Tumor cells % of 
lymphocytes 69 N/A 
Patient age, yrs 57 75 
White blood count, per µL 23,400 63,400 
Lymphocytes% 71 87 
Neutrophils% 24 10 
Metaphase% 0 0 
Blasts% 0 0 
Monocytes% 2 2 
Growth Factor No No 
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Figure 43. Cell death induced by bendamustine and SGI-1776 combination treatment in B-cell 
lymphoma primary cells.  
Primary cells isolated from (A)MCL and (B)SMZL patients were treated with DMSO, or different 
doses of bendamustine (5, 10µM) or 5µM SGI-1776, or combination of these two drugs are these 
concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, then apoptosis levels were 
measured by annexin V/PI positivity measured by flow cytometry.  
B, bendamustine; S, SGI-1776.  
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 In the MCL primary patient sample, bendamustine single agent treatment resulted in low 
levels of apoptosis, 5% and 7% for 5 or 10μM bendamustine, respectively. However, single agent 
SGI-1776 was more effective in cell killing (18%). Combination treatments of 5 or 10μM 
bendamustine + 5μM SGI-1776 killed 18% and 22% of MCL cells, respectively (Figure 43A). Note 
that these numbers were pure cell kill induced by drug treatments ‒in order to prevent 
misunderstanding of the data, the endogenous cell deaths were subtracted from the total values. 
Fractional analysis indicated a less than additive effect in cell killing using this combination method 
in this particular MCL primary sample (Table 4).   
 In the SMZL samples, bendamustine single treatment resulted in less than 10% of cell death, 
whereas 5μM SGI-1776 induced 30% cell death. Combination treatments lead to 35%-37% of 
apoptosis (Figure 43B). Fractional analysis indicated additive effect in cell death in these specific 
SMZL primary cells. 
Aim 3.2. Effect on DNA synthesis inhibition by bendamustine and SGI-1776 combination in JeKo-1.   
To determine the effect of bendamustine and SGI-1776 on DNA synthesis, radioactive 
thymidine incorporation assay was performed in MCL cell line, JeKo-1. JeKo-1 cells were treated 
with bendamustine (5, 10μM) or SGI-1776 (5μM), or combination of the two drugs (5μM or 10μM 
bendamustine+5μM SGI-1776) for 24hr., Radioactively-labeled thymidine was added 45min before 
cell harvest, then incorporated radioactivity was measured using scintillation counter (Figure 44).  
 A reduction of 28% and 51% in DNA synthesis was detected by 5 and 10μM bendamustine 
treatment alone (p=0.04 and 0.03, respectively), whereas 5μM SGI-1776 decreased DNA synthesis 
by 24% of DMSO control. In combination studies, DNA synthesis was reduced to 57% and 40% of 
DMSO control, for 5 or 10μM bendamustine+5μM SGI-1776 treatments (p=0.03 and 0.04, 
respectively).  
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Figure 44. Effect of bendamustine and SGI-1776 combination treatment on DNA synthesis 
inhibition by in JeKo-1 cells.  
JeKo-1 cells were treated with DMSO, bendamustine (5, 10µM) or SGI-1776 (5µM), or combination 
of these two drugs are these concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, 
then cells were incubated with [methyl- 3H]-thymidine at 0.8µCi/mL for 45min. Incorporated 
radioactivity was measured by scintillation counter and values were calculated into DPM/cell which 
was further normalized to DMSO control. Experiments were done in triplicate and results shown are 
average ratios ± SEM. Student t-test was perform to calculate statistical significance.  
B, bendamustine; S, SGI-1776.  
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Compared to 5or 10μM of bendamustine treatment alone, 5 or 10μM bendamustine+5μM SGI-1776 
combination treatments induced statistically significant decrease of DNA synthesis (p=0.02 and 0.1, 
respectively).  
Aim 3.3. Effect on RNA synthesis inhibition by bendamustine and SGI-1776 combination in MCL 
cell line and B-cell lymphoma primary cells.   
 To examine the effect of bendamustine and SGI-1776 on global RNA synthesis, we 
performed uridine incorporation experiment where radioactively-labeled uridine was co-incubated 
with JeKo-1 cells after they were treated with single agent or combination of bendamustine and SGI-
1776 using above concentrations (Figure 45).  
Bendamustine treatment alone did not significantly reduce RNA synthesis levels, with only a 
5% decrease with 10μM. However, consistent with our previous study, SGI-1776 inhibited RNA 
synthesis and a 24% decrease was detected with 5μM of SGI-1776 (Yang 2012). Around 20% 
decrease of global RNA levels were detected when bendamustine and SGI-1776 was combined. 
These changes in RNA synthesis showed a trend for a decrease when cells were treated with both 
drugs, but this was not statistically significant. To evaluate the inhibitory effect of bendamustine or 
SGI-1776 in primary patient cells, PBMCs from patients diagnosed with MCL or SMZL were 
isolated (Table 4), and treated with bendamustine or SGI-1766, or combination of the two drugs, and 
then uridine incorporation was carried out and measured using scintillation counter (Figure 46).  
In MCL primary cells, bendamustine did not reduce the global RNA synthesis level, and 
SGI-1776 treatment alone lead to a moderate decreased of global RNA level (7%). However, when 
used in combination, the RNA synthesis levels were reduced to 76% and 60% of DMSO control, in 
respect of 5 or 10μM bendamustine + 5μM SGI-1776 treatments (Figure 46A).  
In SMZL primary cells, 5 and 10μM of bendamustine caused 7% and 73% decrease in RNA 
synthesis, whereas SGI-1776 was ineffective in reducing RNA synthesis.   
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Figure 45. Effect of bendamustine and SGI-1776 combination treatment on RNA synthesis 
inhibition in JeKo-1 cells.  
JeKo-1 cells were treated with DMSO, bendamustine (5, 10µM), SGI-1776 (5µM), or combination 
of these two drugs are these concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, 
then cells were incubated with [5,6- 3H]-uridine at 0.8µCi/mL for 45min. Incorporated radioactivity 
was measured by scintillation counter and values were calculated into DPM/cell which was further 
normalized to DMSO control. Experiments were performed in triplicate and results shown as 
average ratios ± SEM. Student t-test was perform to calculate statistical significance.  
B, bendamustine; S, SGI-1776.   
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Figure 46. Effect of bendamustine and SGI-1776 combination treatment on RNA synthesis 
inhibition in B-cell lymphoma primary cells.  
PBMCs isolated from (A)MCL and (B)SMZL patients were treated with DMSO, bendamustine (5, 
10µM) , SGI-1776 (5µM), or combination of these two drugs are these concentrations (5 or 10µM 
bendamustine+ 5µM SGI-1776) for 24hr, then cells were incubated with [5,6- 3H]-uridine at 
0.8µCi/mL for 45min. Incorporated radioactivity was measured by scintillation counter and values 
were calculated into as DPM/cell and were further normalized to DMSO control.  
B, bendamustine; S, SGI-1776.  
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When used in combination, 5 or 10μM bendamustine + 5μM SGI-1776 lead to 4% and 79% of RNA 
synthesis decrease compared to DMSO control (Figure 46B).  
These data suggest that SGI-1776 was more effective in reducing global RNA synthesis in 
replicating cell lines whereas bendamustine was more effective in quiescent primary B-cell 
lymphoma samples; combination of the two drugs was also effective in reducing global transcription 
levels.  
Aim 3.4. Effect on protein synthesis inhibition by bendamustine and SGI-1776 combination in MCL 
cell line and B-cell lymphoma primary cells.   
SGI-1776 is known to target protein synthesis in MCL cell lines and primary samples, as 
shown in our previous study (Yang 2012). It is also known that bendamustine lead to DNA damage 
which further causes disruption of DNA synthesis repair and transcription processes (Gandhi 2009; 
Rummel 2011). Hence, we hypothesize that SGI-1776-induced global translation inhibition is 
maintained or enhanced in the presence of bendamustine. 
To investigate the effect of bendamustine and SGI-1776 treatment on protein synthesis, we 
treated JeKo-1 cells with bendamustine, SGI-1776, or combination of the two drugs, and then 
performed leucine incorporation experiments to analyze the reduction of protein synthesis caused by 
these treatments (Figure 47).  
Bendamustine treatment (5, 10μM) reduced protein synthesis levels by 10%-13%, whereas 
SGI-1776 (5μM) brought it down to 60% of control. In combination studies, 5 or 10μM of 
bendamustine + 5μM of SGI-1776 reduced protein synthesis to 68% and 54% of DMSO control 
( p<0.05, respectively). Additionally, both 5μM bendamustine+5μM SGI-1776 lead to statistically 
significant decrease of protein synthesis compared to 5μM bendamustine alone (p=0.06).  
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Figure 47. Effect of bendamustine and SGI-1776 combination treatment on protein synthesis 
inhibition in JeKo-1 cells.  
JeKo-1 cells were treated with DMSO, bendamustine (5, 10µM), SGI-1776 (5µM), or combination 
of these two drugs are these concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, 
then cells were incubated with [4,5- 3H]-L-leucine at 0.8µCi/mL for 45min. Incorporated 
radioactivity was measured by scintillation counter and values were calculated into DPM/cell and 
were further normalized to DMSO control. Experiments were done in triplicate and results shown as 
average ratios ± SEM. Student t-test was perform to calculate statistical significance.  
B, bendamustine; S, SGI-1776.  
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To confirm the effect of bendamustine and SGI-1776 on protein synthesis, we used the 
PBMCs isolated from MCL or SMZL patient samples and conducted leucine incorporation 
experiments to measure the decrease of protein synthesis in these model systems (Figure 48).  
In MCL sample, 5 and 10μM of bendamustine reduced protein synthesis to around 50% of 
DMSO control, whereas 5μM SGI-1776 decrease this level to 42% of control. In combination 
treatment, protein synthesis levels were reduced to 28% and 42% of DMSO control, in respect of 5 
or 10μM of bendamustine + 5μM of SGI-1776 treatment, respectively (Figure 48A).  
In SMZL sample, interestingly, only 5μM of bendamustine treatment decreased protein 
synthesis level (85% of control), but not 10μM treatment. 5μM of SGI-1776 reduced protein 
synthesis by 5%. When used together, protein synthesis decreased to 63% and 75% of DMSO 
control, for 5 or 10μM of bendamustine + 5μM of SGI-1776 treatment, respectively (Figure 48B).  
 These data indicated that bendamustine was more effective in reducing global protein 
synthesis in quiescent primary B-cell lymphoma than in replicating JeKo-1 cells. SGI-1776 alone 
and combination with bendamustine were both effective in reducing global protein synthesis in both 
model systems. 
Aim 3.5. Effect on DNA damage marker γ-H2AX by bendamustine and SGI-1776 combination in 
JeKo-1 cells.   
 To determine whether addition of SGI-1776 affects bendamustine-induced DNA damage 
response, we performed immunostaining of JeKo-1 cells to analyze changes in the levels of phospho-
Histone 2A variant X (H2AX) at Ser139, also known as γ-H2AX, following bendamustine and SGI-
1776 combination treatments.   
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Figure 48. Effect of bendamustine and SGI-1776 combination treatment on protein synthesis 
inhibition in B-cell lymphoma primary samples.  
PBMCs isolated from (A)MCL and (B)SMZL patients were treated with DMSO, bendamustine (5, 
10µM), SGI-1776 (5µM), or combination of these two drugs are these concentrations (5 or 10µM 
bendamustine+ 5µM SGI-1776) for 24hr, then cells were incubated with [4,5- 3H]-L-leucine at 
0.8µCi/mL for 45min. Incorporated radioactivity was measured by scintillation counter and values 
were calculated into DPM/cell and were further normalized to DMSO control.  
B, bendamustine; S, SGI-1776.  
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 JeKo-1 cells were treated with bendamustine (5, 10μM), with or without 5μM SGI-1776, 
then cells were fixed and stained with primary antibodies to detect γ-H2AX (Ser139), as a measure 
for DNA damage (Figure 49).   
Consistent with our hypothesis, DNA damage was detected in bendamustine-treated cells, 
with an increase of 14% and 49% of positive γ-H2AX levels with 5 and 10μM bendamustine, 
respectively. Addition of SGI-1776 did not resulted in significant increase in γ-H2AX 
phosphorylation. In combination, 13% and 38% of positive γ-H2AX were detected for 5, 10μM 
bendamustine +5μM SGI-1776 treatments, indicating that SGI-1776 did not significantly augment 
bendamustine-induced γ-H2AX formation, and bendamustine-induced DNA damage repair is 
maintained.  
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Figure 49. Effect of SGI-1776 treatment on bendamustine-induced γ-H2AX expression in 
JeKo-1 cells.  
JeKo-1 cells were treated with DMSO, bendamustine (5, 10µM), SGI-1776 (5µM), or combination 
of these two drugs are these concentrations (5 or 10µM bendamustine+ 5µM SGI-1776) for 24hr, 
then cells were harvested and fixed by cold 70% ethanol overnight. Cells were then washed and 
incubated with 0.5% goat serum for 1hr, then probed with primary antibody phospho-histone γ-
H2AX (1:500) for 2hr followed by secondary antibody Alexa Fluor mouse IgG (1:200) for 1hr. Cells 
were then washed and co-incubated with a mixture of 10µg/mL propidium iodine and 2.5µg/mL 
DNAse-free RNAse for 15min. Cells were analyzed for fluorescence signal shift using flow 
cytometry to detect the extensiveness of DNA damage. Fluorescence-positive cells were marked as 
γ-H2AX positive and results were normalized by subtracting endogenous γ-H2AX levels in DMSO-
treated cells. Experiments were done in triplicate and results were shown as average ratios ± SEM. 
Student t-test was perform to calculate statistical significance.  
B, bendamustine; S, SGI-1776.  
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CHAPTER 5: Discussion and Conclusion  
I. Summary 
Our results indicated that all three Pim kinases are expressed in MCL cell lines and primary 
tissue sample (Figures 5-6). Pim kinases are potential therapeutic targets in MCL as Pim kinase 
inhibitor, SGI-1776 treatment induced moderate to high levels of apoptosis in four MCL cell lines 
(JeKo-1, Mino, SP-53 and Granta-519) as well as in PBMCs isolated from primary MCL patient 
samples but not healthy donors (Figures 7-12, 30-33). Primary mechanism of actions of SGI-1776 
appears to be targeting c-Myc-driven transcription and cap-dependent translation processes (Figures 
13, 15, 30). In addition, levels of short-lived oncoproteins, Mcl-1 and cyclin D1 were decreased in 
MCL cell line JeKo-1, and primary MCL samples (Figures 18-19, 23, 30). Moreover, SGI-1776 
treatments also lead to decline of global RNA synthesis levels in MCL cell lines, correlating with 
decrease of MCL1 mRNA level in these cell lines (Figures 17-18). Meanwhile, MCL1 mRNA levels 
were also decreased in malignant PBMCs from MCL patients but not in normal PBMCs (Figures 34-
35). Collectively, our study suggests Pim kinases as viable drug targets in MCL and that SGI-1776 
primarily target Pim kinase functions through disruption transcriptional and translational regulations.  
Our studies using bendamustine in combination with SGI-1776 also revealed some 
interesting results. With bendamustine treatment alone, we observed moderate level of apoptosis in 
MCL cell lines (JeKo-1 and Mino) as well as in MCL and SMZL primary cells from patients 
(Figures 42-43). An additive or synergistic effect in cell killing was observed when combined with 
SGI-1776 (Figure 42-43). SGI-1776 treatment was effective in decreasing global RNA and protein 
synthesis levels, while bendamustine inhibited DNA synthesis and generated DNA damage response 
(Figures 44-49). When used in combination, we observed intensified inhibitory effects in DNA, 
RNA and protein syntheses compared to single agent treatments of either drug (Figures 44-49).  
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To incorporate main findings of my dissertation, I use a model that summarizes the dissertation 
project and the cause-and-effect relationships (Figure 50). 
Together, these data provided a rationale for using Pim kinase inhibitor in combination with 
bendamustine, and suggested feasibility of such therapeutic approach in B-cell lymphoma.  
II. SGI-1776 primary mechanisms of actions in MCL  
MCL cell lines as primary model of study  
Primary objective of our investigation was to test Pim kinase inhibition in MCL. This is the 
first investigation of Pim kinase inhibitor, SGI-1776 in this type of B-cell lymphoma. To fully 
evaluate consequences of Pim kinase inhibition and to establish our results, we used both MCL cell 
lines and primary malignant B-cell lymphoma from patients. Furthermore, to explore broad 
applicability, we used a spectrum of MCL cell lines. These four MCL cell lines possess different 
cellular morphology, ranging from non-attached single cells to small or large clumps. They acquire 
different growth media, and doubling time varies from 24-72hr. However, all four cell lines possess 
hallmark features of MCL such as t(11;14)(q13;q32), cyclin D1 expression (Table 6) and typical 
MCL surface markers, CD19/20+ (Table 7) (Morice 2008). In addition, these MCL cell lines express 
cyclin E protein, but very low levels of cyclin D2/D3, while c-Myc, p21 and p27 levels are present in 
all (Table 8). Meanwhile, anti-apoptotic Bcl-2 family proteins such as Bcl-2, Bcl-XL, and Mcl-1 and 
pro-apoptotic Bax are present in all cell lines (Table 9).  
Interestingly, discrepancies were observed in JeKo-1 and Mino cell lines in SGI-1776-
induced responses in the cells, such as apoptosis, disruption of phosphorylation of Pim kinase targets, 
decrease of global RNA synthesis inhibition and Mcl-1mRNA and protein levels as well as cell cycle 
arrest (Figures 7-24). JeKo-1 cells were more sensitive and responsive to SGI-1776 treatment 
compared to Mino cells. Based on the known genetics and molecular characteristics of these two cell 
lines, we cannot conclude the possible causes of these discrepancies. A gene array or reverse-phase
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Figure 50. An overall model to summarize main findings.  
Figure 50.  
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Table 6.  
 
 
 
 
 
  JeKo-1 Mino Granta 519 SP-53 
Growth pattern Single cell Single cell Small clumps Large clumps 
Culture media RPMI 1640+10%FBS 
RPMI 
1640+20%FBS DMEM + 20%FBS 
RPMI 
1640+20%FBS 
Doubling time 24hr 24hr 24-72hr 72hr 
t(11:14) (q13;q32) Positive Positive Positive Positive 
cyclin D1 
expression High positive Positive Positive Positive 
 
 
 
 
 
 
 
 
Table 6. MCL cell lines growth condition and MCL charateristics.  
Adapted from [Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, 
Keating MJ, Lai R, Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 
2003;127(4):426] with permission from Archives of Pathology & Laboratory Medicine. Copyright 
2003 College of American Pathologists. 
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Table 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Surface CD markers of MCL cell lines.  
Adapted from [Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, 
Keating MJ, Lai R, Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 
2003;127(4):427] with permission from Archives of Pathology & Laboratory Medicine. Copyright 
2003 College of American Pathologists. 
  
  JeKo-1 Mino Granta 519 SP-53 
CD5 + + - - 
CD10 + - - - 
CD19 + + + + 
CD20 + + + + 
CD22 +  n/a n/a n/a 
CD23 - - + + 
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Table 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Oncogene, tumor suppressor and cell cycle marker expressions in MCL cell lines.  
w―weak 
s―strong 
*p27 band was detected at 53kD in JeKo-1 
Adapted from [Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, 
Keating MJ, Lai R, Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 
2003;127(4):428] with permission from Archives of Pathology & Laboratory Medicine. Copyright 
2003 College of American Pathologists. 
 
  
  JeKo-1 Mino Granta 519 SP-53 
Cyclin D2 - - - - 
Cyclin D3 + (w) - - + (w) 
Cyclin E + + + + 
Rb + + + + 
c-Myc + + + + 
p21 + + + + 
p27 +* + + + 
p53 - + +(s) + 
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Table 9.  
 
 
 
  JeKo-1 Mino Granta 519 SP-53 
Bcl-2 + + + + 
Bcl-XL + + + + 
Bcl-XS - - - - 
Bax + + + + 
Mcl-1 + + + + 
 
 
 
 
 
 
Table 9. Bcl-2 family protein expressions in MCL cell lines.  
Adapted from [Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, 
Keating MJ, Lai R, Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 
2003;127(4):428] with permission from Archives of Pathology & Laboratory Medicine. Copyright 
2003 College of American Pathologists. 
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protein array (RPPA) may be used as exploratory approaches to detect their detailed molecular 
characteristics, both before and after drug treatment. These array-type studies could potentially 
reveal inherent genomic differences and differentially regulated genes and proteins related to drug 
resistance, or other factors that may have contributed to the differences in responding to drug 
treatments.   
Primary patient samples as important predictor of drugs’ clinical outcomes 
In our studies, we used primary samples from MCL patients as well as apparently healthy 
donors to study the effect of SGI-1776 on cell killing, and to identify potential biomarkers of SGI-
1776 in the clinic. Notably, we only detected SGI-1776-induced apoptosis, decrease of Pim kinase 
phosphorylation targets and short-lived oncogenes in lymphocytes isolated from MCL patient blood 
but not in PBMCs isolated from healthy donors (Figures 30-35). These results suggested a favorable 
therapeutic index of SGI-1776 in the clinic, as it selectively targets malignant cells. Our investigation 
did not address the reasons behind this phenomenon, except that more consistent expression of these 
oncogenic proteins were detected in MCL primary cells compared to those of healthy donors. More 
in-depth study of these cells, such as RPPA studies to identify their molecular characteristics, 
expression levels of target proteins, and cellular metabolism patterns are needed to unravel these 
differential biological responses.  
Targeting c-Myc-driven transcription 
Because Pim kinases are expressed in MCL cell line and primary tissue samples (Figures 5-
6), they act as model system to investigate mechanism of action of SGI-1776. Among all proteins, c-
Myc is one of the fastest degrading proteins in human cells (Gregory 2000). Post-translational 
modifications, however, alter the short half-life of c-Myc. It has been reported that Pim-1 directly 
phosphorylates c-Myc at Ser62, the stabilization site on the protein to prolong its half-life from 
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minutes to hours, which promotes c-Myc oncogencity (Sears 2000; Zhang 2008). While we did not 
evaluate half-life of c-Myc, we examined phospho-c-Myc (Ser62) levels in both MCL cell lines and 
primary cells following SGI-1776 treatment, and observed a consistent decrease in all cells tested 
(Figures 13, 30). This result confirmed that in MCL, c-Myc is a target of Pim kinases.  
 Noticeably, along with a decline in phospho-c-Myc (Ser62) levels, there was also a decrease 
of total c-Myc levels, especially in JeKo-1 cells (Figures 13, 30). In JeKo-1 cells, total c-Myc 
seemed to decrease more profoundly than phospho-c-Myc (Ser62) (Figure 13A). This is an 
unavoidable situation since c-Myc (Ser62) phosphorylation is a protein stabilization site for c-Myc, 
and when Pim kinase function is inhibited by SGI-1776, c-Myc is degraded more rapidly (Zhang 
2008). In addition, we consistently observed that the total c-Myc primary antibody used in this 
immunoblot does not generate as strong signals as the c-Myc (Ser62) antibody; the quality difference 
in these primary antibodies may also contribute to these results.  
It was also reported that Histone H3 phosphorylation at Ser10, a target for Pim kinase, is a 
critical step to enhance c-Myc-driven transcription (Zippo 2007). However, only in JeKo-1 cells but 
not Mino, phospho-Histone H3 (Ser10) was reduced upon SGI-1776 treatment (Figure 14). We 
hypothesize that SGI-1776 prevents Pim kinase from phosphorylate c-Myc (Ser62) and Histone H3 
(Ser10) which consequently disrupts c-Myc-driven transcription (Figure 51). Notably, Zippo et al. 
performed their experiments in serum-starved condition, whereas our experiments were done in full-
serum condition, an experimental condition that could have contributed to the difference in results. 
Consistent with c-Myc data, total RNA synthesis declined in all four MCL cell lines (Figure 17A).  
Importantly, levels of apoptosis in both MCL cell lines and primary samples were positively 
correlated with decrease of phospho-c-Myc level in MCL cell lines. In addition, strong correlation 
was observed between c-Myc phosphorylation and global RNA synthesis as well as MCL1 mRNA  
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Figure 51. SGI-1776 treatment decreases transcription by disrupting phosphorylation of c-Myc 
and Histone H3.  
SGI-1776 disrupts Pim kinase function, therefore reduced the c-Myc and Histone phosphorylation 
levels and lead to disruption of Myc-Max complex formation. These processes eventually disrupt c-
Myc-driven transcription machineries.   
Figure	51.		
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levels, suggesting a c-Myc-driven transcription is involved with SGI-1776 mechanisms of action 
(Figures 37-38).  
Targeting cap-dependent translation 
Phosphorylation of 4E-BP1 (Thr37/46) is prerequisite for 4E-BP1 hyper-phosphorylation, 
which leads to dissociation from eIF4 translation initiation factor (Gingras 2001). Unbound eIF4 will 
initiate cap-dependent protein translation, a process for translating early response gens including Pim 
kinases (Hoover 1991; Richter 2005). Pim-1 is known to phosphorylate 4E-BP1 at Thr37/46 site, 
which triggers hyper-phosphorylation of this protein (Gingras 2001; Tamburini 2009). Pim-2 also 
phosphorylates 4E-BP1 at Ser65 as part of the hyper-phosphorylation process (Fox 2003). We 
observed that the 4E-BP1 (Thr37/46) phosphorylation level was consistently decreased in JeKo-1, 
Mino cell lines and MCL primary samples following SGI-1776 treatment (Figures 15, 30). Our 
results suggest that SGI-1776 prevents 4E-BP1 priming by Pim kinases which then targets cap-
dependent translation processes (Figure 52).  
Targeting cell survival machinery  
All three Pim kinases phosphorylate Bad protein (Ser112), a pro-apoptotic Bcl-2 family 
member (Yan 2003; Aho 2004). Un-phosphorylated Bad protein is bound to Bcl-2 family protein 
(Bcl-XL or Bcl-2) to sequester their anti-apoptotic function. Once Bad is phosphorylated at Ser112, it 
dissociates from Bcl-XL and bind with scaffold protein 14-3-3, where it gets shuttled into the 
cytoplasm (Aho 2004). Hence, SGI-1776 treatment may lead to a decrease of Bad (Ser112) 
phosphorylation, which could be a contributing factor to the extensive apoptosis by SGI-1776 
treatment observed in MCL cells (Figure 53).  
We measured the Bad (Ser112) phosphorylation levels in MCL cell lines JeKo-1 and Mino 
following SGI-1776 treatment, and interestingly, we were only able to detect a decrease in Bad 
(Ser112) phosphorylation in JeKo-1 cells but not in Mino cells (Figure 16).  
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Figure 52. SGI-1776 treatment decreases translation by disrupting phosphorylation of 4E-BP1.  
SGI-1776 disrupts Pim kinase function, therefore reduced the 4E-BP1 phosphorylation levels and 
lead to disruption of initiation of cap-dependent translation.  
  
Figure 52.  
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Figure 53. SGI-1776 treatment disrupts phosphorylation of Bad which contribute to cell death.  
SGI-1776 disrupts Pim kinase function, therefore reduced the Bad phosphorylation levels and lead to 
re-gaining function of Bad. Un-phosphorylated Bad also associates with anti-apoptotic Bcl-XL which 
then leads to further induction of apoptosis.   
Figure	53.		
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In addition, the degree of Bad (Ser112) decrease was less extensive as the level of apoptosis, 
suggesting that this is not a primary mechanism of action of SGI-1776 in MCL cells (Figures 11, 16).  
Furthermore, disruption of c-Myc (Ser62) and 4E-BP1 (Thr37/46) phosphorylation may also 
lead to cell death following SGI-1776 treatment in MCL cells. However, a time course experiment is 
needed to correlate decrease of phosphorylation of c-Myc and 4E-BP1 with SGI-1776-induced 
apoptosis to establish the cause and effect and temporal relationship of these events. Since c-Myc 
and 4E-BP1 are direct targets of Pim kinases, and decreased phosphorylation of these two proteins 
lead to disrupted c-Myc-driven transcription and cap-dependent translation, we hypothesize that 
decrease of phosphorylation levels of these two protein markers would appear prior to extensive cell 
death, indicating that SGI-1776-induced cell killing is a result of targeting c-Myc and 4E-BP1 
phosphorylation by this drug.  
Moreover, to establish causal role of c-Myc and 4E-BP1 phosphorylation in cell death, 
functional inhibitors of c-Myc and 4E-BP1may be tested separately and in combination in MCL cell 
lines. Alternatively, siRNA treatments to knockdown each protein may establish their roles that 
disruption of c-Myc and 4E-BP1 phosphorylation lead to cell killing and suggest that SGI-1776-
induced apoptosis was through inhibition of c-Myc and 4E-BP1 phosphorylation.  
Nonetheless, since c-Myc-driven transcription and cap-dependent translation processes were 
consistently affected by SGI-1776 treatments, therefore, we hypothesized that early response genes 
that are regulated by cap-dependent translation may be affected, and those with oncogenic nature, 
such as Mcl-1 and cyclin D1 may be affected and contributed to the extensiveness of apoptosis 
induction by SGI-1776 treatment (Fox 2003; Khoury 2003; Schatz 2011).  
We tested the levels of Mcl-1 and cyclin D1 in MCL cell lines and primary cells, and 
detected a consistent decrease of Mcl-1 levels in both cell lines and MCL primary samples (Figures 
19-20, 23, 30). Notably, the decrease of anti-apoptotic proteins did not occur in proteins with longer 
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half-lives such as Bcl-2 and Bcl-XL (Figure 21). Importantly, in both JeKo-1 and Mino cells, 
decrease of Mcl-1 protein was detected as early as 0.5hr and lasted through the rest of 24hr.  
Consistently, there was a significant decrease of MCL1 mRNA levels in both MCL cell lines and 
primary samples; and in cell lines, MCL1 levels started to decrease at 0.5hr as well (Figures 18, 34). 
These observations suggest that Mcl-1 mRNA and protein are rapidly degraded by SGI-1776 
treatment, which may contribute to the SGI-1776-induced apoptosis in these MCL cells.  
In contrast, we detected heterogeneous outcomes in cyclin D1 levels between the two MCL 
cell lines. There was a significant and consistent decrease of cyclin D1 levels in JeKo-1 cells, but the 
opposite was observed in Mino cells (Figure 24). Notably, cyclin D1 levels in untreated Mino cells 
were much lower than that of JeKo-1 cells. However, in malignant PBMCs isolated from MCL, we 
detected consistent decrease of cyclin D1 levels (Figure 31). These results indicated that cyclin D1 
degradation could be a contributor for high levels of apoptosis in cells express high levels of cyclin 
D1 but not in cells express low levels of this protein.  
Importantly, in PBMCs isolated from MCL patient in remission or healthy donors, we did 
not detect a decrease of either 4E-BP1 (Thr37/46), or c-Myc (Ser62) phosphorylation levels after 
treated with SGI-1776, and we detected low levels of apoptosis in these samples (Figure 32). In 
concordance, neither did Mcl-1, cyclin D1 protein levels, nor MCL1 mRNA levels decrease in 
normal PBMCs following SGI-1776 treatment (Figures 33, 35). These observations suggests that 
SGI-1776 is not toxic in these normal PBMCs, and it does not alter the molecular mechanisms of 
healthy cells, suggesting that SGI-1776 is therapeutically favorable, and support its feasibility in the 
clinic.  
Targeting cell cycle 
Pim kinases are known to target multiple cell cycle proteins, such as p21, p27, cdc25A/C 
(Figure 2). Phosphorylation of these cell cycle-regulating proteins promote cells to enter G1/S and 
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G2 phases more efficiently, which makes them more oncogenic in nature (Mochizuki 1999; Wang 
2002; Bachmann 2006; Morishita 2008).  
Differential effect was observed in cell cycle profile between the two MCL cell lines. In 
JeKo-1, there wasn’t obvious signs for cell cycle arrest, however, in Mino, a dose-dependent G1 
phase arrest was detected (Figure 22). Unfortunately, we could not find a well-functioned p21 
antibody for western blot analysis, and p27 expression was irregular, running at 54kD in Mino cells 
and we could not detect p27 expression JeKo-1 cells (data not shown). Therefore, we were not able 
to analyze these two protein marker responsible to regulate G1 phase. We also analyzed the cdc25C 
phosphorylation level in the two MCL cell lines. It seemed that in JeKo-1, both phospho- and total 
cdc25C expression levels were reduced upon SGI-1776 treatment, and total cdc25C level decreased 
faster and more significant than the phospho-cdc25C (Figure 23). However, we did not detect any 
changes in phospho-cdc25C level in Mino cells. It seems that G1 arrest may be a cell type-specific 
phenomenon.  
Short-lived oncogene cyclin D1 is also a cell cycle-regulating protein. Cyclin D1 forms 
complexes with CDK 4/6, both are expressed at high levels in MCL, which regulates G1/2 transition 
(Perez-Galan 2011). We analyzed the changes of cyclin D1 levels in JeKo-1 and Mino, and we 
observed opposite response as described above (Figure 24). Besides the differential expression levels 
of cyclin D1 in untreated JeKo-1 and Mino, the contracting cell cycle profiles of JeKo-1 and Mino 
caused by SGI-1776 suggests that cyclin D1 may be regulated differently in the two cell lines.  
Pim kinase redundant pathways  
In our SGI-1776 single agent treatment study in MCL, we consistently detected decrease of 
c-Myc (Ser62), 4E-BP1 (Thr37/46) and Mcl-1 mRNA and protein levels in all the in vitro models 
tested. However, even taken all of the factors above, these may still not be enough to compensate 
with the extensiveness of apoptosis observed in these cells. We hypothesize that redundant pathways 
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to Pim kinase pathways may be contributing to this phenomenon, such as the PI3K/Akt/mTOR and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) canonical pathways, which 
are also upregulated in MCL (Hammerman 2005; Schatz 2011). These pathways share some 
common targets such as c-Myc, 4E-BP1, and a common effector Mcl-1, as well as upstream growth 
factors and cytokines/chemokines (Hammerman 2005; Chen 2010; Fruman 2011; Nawijn 2011). A 
gene-array and a RPPA assay will be useful to identify these potential redundant pathways, and it is 
important to perform these assays both before and after SGI-1776 treatments in multiple MCL cell 
lines, and compare the SGI-1776-induced changes in different oncogene and oncoproteins in their 
regulating oncogenic pathways, In addition, these screening tests could also reveal additional factors 
contributing to the extensive cell death observed in the MCL cells.  
Our siRNA knockdown studies showed results in accord with the hypothesis of activated 
redundant pathways in MCL cells, that even when Pim kinase mRNAs are knocked down to almost 
50% or less than scrambled control, Pim kinase phospho- targets (c-Myc, 4E-BP1) and Mcl-1 protein 
showed less extensive level of decrease in their phosphorylation levels, which could be due to 
activation of the redundant pathways (Figures 13, 15, 25-29).  In addition, less extensive cell death 
levels compared to SGI-1776 treatment were detected in MCL cells treated with Pim kinase siRNAs 
(Figures 11-12, 25-29). This result indicates that other targets may be impacted by SGI-1776 besides 
Pim kinases. However, our siRNA treatment results were consistent with Pim kinase knockout 
mouse embryonic fibroblast (MEF) cells. These Pim kinase knockout MEFs grow and replicate 
much more slowly compared to wildtype MEF cells (Beharry 2011). Other means of cell death by 
SGI-1776 remains to be found, such as other short-lived oncogenic proteins and possibly other 
transcription/translation-regulating pathways, which may be discovered through microarrays and 
RPPA assays.    
SGI-1776 toxicity and second generation Pim kinase inhibitors 
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 SGI-1776 was the first Pim kinase inhibitor to enter clinical trial for refractory prostate 
cancer or lymphoma, but it was terminated prematurely due to cardiotoxicty, concerns when 
prolonged cardiac QTc was observed in patients treated with SGI-1776 (ClinicalTrial.gov). This was 
an unexpected human-only toxicity as it was not observed in other animals during in vivo testing 
during drug development (Astex Pharmaceuticals). A possible reason may be that both Pim-1 and 
Pim-3 are expressed in human cardiomyocytes, and may be cytoprotective against external toxicities 
and injuries (Liu 2009; Borillo 2010). In addition, several metabolites of SGI-1776 were observed in 
human plasma (verbal communication with SuperGen, now Astex Pharmaceuticals) and hence a 
more stable and targeted inhibitor was in demand.  
A plethora of Pim kinase inhibitors is synthesized by several pharmaceutical companies. 
Several of these next generation Pim kinase inhibitors have been tested in in vitro assays (SMI-4a), 
pre-clinical trial (GNE-652) or clinical trial (AZD-1208); more are underway (Beharry 2011; Keeton 
2011; Munugalavadla 2011; Blanco-Aparicio 2012; Keeton 2012). Preliminary data from AZD-1208 
in AML cells and AML clinical trials were presented recently (Keeton 2012).  
Pim kinases targeting appears to be a valid option for MCL, however, cell death data suggest 
that combination strategies are needed. Especially for drugs that act synergistically, much lower 
doses of each drug in the combination method are needed for achieving desired clinical efficacy. 
These potential partners could be members of the conventional chemotherapeutic drugs that target 
multiple oncogenic pathways, or targeted therapeutic inhibitors that have specific targets, as long as 
the combination treatment reaches the goal of repressing multiple redundant oncogenic pathways and 
lead to sufficient amount of cytotoxicity in cancer cells. To date, no information on SGI-1776’s 
synergy partners has been reported; we investigated a combination approach using bendamustine, a 
FDA-approved chemotherapeutic agent with SGI-1776, and tested the molecular responses in B-cell 
lymphoma cells.       
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III. Combination of bendamustine with SGI-1776 in B-cell lymphoma  
Bendamustine is a DNA damaging agent that causes both inter- and intra-strand DNA 
crosslinks, which lead to disruption in DNA replication, repair and transcription processes (Leoni 
2011). Single-drug bendamustine treatment during clinical trials showed promising efficacy with 
overall response rate at >70% and duration of response as >9 months, although toxicity was observed 
in both non-hematological and hematological nature (National Cancer Institute). Overall, this drug is 
well-tolerated by patients (Goy 2011). Based on our results with SGI-1776, c-Myc-driven 
transcription and cap-dependent-translation appear to be primary mechanisms of action, and the 
molecular mechanism as well as favorable clinical efficacy of bendamustine, we speculate that 
bendamustine is an appropriate agent to be combined with SGI-1776 and we expect an additive 
effect in cell killing in B-cell lymphoma cells (Figure 42-43). We examined the effect of each drug 
as well as the combination approach on aspects of DNA, RNA and protein synthesis inhibition along 
with cell death in B-cell lymphoma cell lines and primary patient samples, as described in details 
below.    
Targeting DNA synthesis 
 Bendamustine demonstrates a unique cytotoxicity profile compared to other alkylating 
agents, which involves induction of caspase-dependent and -independent apoptosis (Roue 2008), 
increased DNA repair gene expression through base excision repair and S-phase arrest (Torres-
Garcia 1989), as well as degrading mitotic checkpoint-regulating proteins that disrupts G2-M 
transition which ultimately results in mitotic catastrophe (Leoni 2011).  
Gamma-H2A is a known marker for DNA double-stranded breaks, which is associated with 
DNA inter-strand crosslinks (Leoni 2008). Gamma-H2A phosphorylation is an important step for 
recruiting DNA repair proteins and cell cycle-checkpoint proteins to the site of DNA damage, and 
can be detectable by flow cytometry (Paull 2000; Fillingham 2006). Our studies showed that single-
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agent bendamustine treatment in MCL cell line JeKo-1 was effective in inducing γ-H2A, especially 
at higher concentrations (15%-50% induction at 5-10μM, Figure 49). In addition, single agent 
bendamustine was also effective in disrupting global DNA synthesis in JeKo-1, measured by 
radioactive-thymidine incorporation assay, which is also consistent with previous findings (30%-50% 
reduction, Figures 44).   
 Since SGI-1776 single agent treatment on DNA damage in MCL cells is unknown, we used 
thymidine incorporation assay to detect the changes on level of DNA synthesis and found that SGI-
1776 was less effective in reducing DNA synthesis levels compared to bendamustine (24% reduction, 
Figure 44). In addition, we did not see increased levels of γ-H2A from SGI-1776 treatment alone 
(Figure 49). These results are expected, as the primary mechanism of action of SGI-1776 in MCL 
cells appears to be through transcription and translation inhibition, which are both are downstream of 
DNA synthesis. Interestingly, combination of bendamustine with SGI-1776 showed additive effect in 
blocking global DNA synthesis in JeKo-1 cells without showing an increase in γ-H2A induction 
(Figures 44, 49). For future studies, molecular markers related to DNA damage and repair, such as 
p53, ATM, and cell cycle checkpoint proteins and aurora kinases may play a role in this process and 
are potentially relevant clinical markers for studying DNA damage response using bendamustine 
with a Pim kinase inhibitor.      
Targeting RNA synthesis 
 Our study has demonstrated that SGI-1776 targets c-Myc-driven transcription process and 
also reduced global RNA synthesis levels in MCL (Yang 2012). Bendamustine, a DNA-damaging 
alkylating agent, is known to break DNA crosslinks which halts DNA synthesis, and subsequently 
results in transcription inhibition (Leoni 2008).  
Using radioactive-uridine incorporation in JeKo-1 cells and B-cell lymphoma primary cells 
to measure RNA synthesis, single agent SGI-1776 resulted in significant decrease in RNA synthesis, 
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whereas in bendamustine-treated cells, there was little or no effect (Figures 45-46). More significant 
decrease in global RNA synthesis was observed in the MCL and SMZL primary samples compared 
to JeKo-1 cell line using combination treatments (Figures 45-46). This may be due to the difference 
in cellular physiology between replicating cell line and non-proliferating primary cells, where the 
relevant transcription regulator proteins are expressed differently. This result needs to be further 
explored in a larger number of cell lines and primary samples and the regulating molecules needs to 
be validated.  
Targeting protein synthesis 
 Our previous study indicated inhibition of 4E-BP1-mediated cap-dependent translation as a 
mechanism of action of SGI-1776 in MCL cells (Yang 2012). Our experiments using radioactive-
leucine incorporation assay confirmed this finding that SGI-1776 was effect in reducing global 
translation levels in both JeKo-1 cell line and MCL, SMZL primary samples (10%-60% decrease, 
Figures 47-48).  
Bendamustine has not been demonstrated to affect translation processes; however, our 
results indicated a 13%-50% decrease of global protein synthesis level using single agent 
bendamustine in both MCL cell line and primary cells, with variability among the two primary B-
cell lymphoma samples (Figure 47, 48). We suspect that this was not a direct effect but rather a 
secondary or tertiary result, following bendamustine-induced DNA damage response and disruption 
of transcription process. However, the decrease of global protein synthesis by bendamustine was 
extensive, suggesting that there may be an unknown mechanism of action that contributed to this 
result. To confirm this hypothesis, further explorations and molecular studies are needed.  
Combination of bendamustine and SGI-1776 resulted in variable responses in global protein 
synthesis inhibition in JeKo-1 cell lines and B-cell lymphoma primary samples. Heterogeneity 
among patient samples may be a reason, however, consistent in both JeKo-1 and primary patient 
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samples, combination treatment lead to more significant decrease in global protein levels compared 
to either single agent treatment (Figures 48, 48). Interestingly, similar to uridine-incorporation 
studies, more prominent results were shown in primary MCL patient cells compared to cell lines. 
Greater number of cells lines and primary patient cells are needed to verify these results and 
understand the molecular mechanism.   
Additive to synergistic effect in cell killing 
 Both bendamustine and SGI-1776 are cytotoxic agents (Leoni 2008; Yang 2012), and based 
on the known mechanisms of actions, we hypothesized that when used in combination, there would 
be an additive to synergistic effect in cell killing in B-cell lymphoma cells (Figure 41). We used 
annexin V/PI assays to analyze the apoptosis induction by each agent alone, and in combination then 
used fractional analysis to determine whether the results were less than, equal to or more than 
additive (Figures 42-43, Table 3).  
 In MCL cell lines, JeKo-1 and Mino, we observed additive to synergistic effects in apoptosis 
(Figure 42). In the two B-cell lymphoma samples, we observed additive effects (Figure 43). 
Although the molecular mechanisms were not investigated, our results measuring apoptosis 
induction, as well as the results on macromolecule synthesis inhibition, suggested that combination 
of bendamustine with a Pim kinase inhibitor such as SGI-1776 could be a viable therapeutic 
approach in the clinic. A larger number of cell lines and primary cells are needed to conduct 
molecular marker studies in order to identify the underlying mechanisms of actions.  
Other combination methods involving Pim kinase inhibitors  
  Combination strategies using small molecule inhibitors or established chemotherapeutic 
agents with Pim kinase inhibitors have been investigated to augment cytotoxicity in both 
hematological malignancies and solid tumors. In prostate cancer, where Pim kinases contribute to 
tumorigenesis and chemoresistance, Pim kinase inhibitor, SMI-4a was used in combination with  
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Bcl-2 inhibitor, ABT-737, which is also a clinical trial agent, to overcome chemoresistance and 
successfully boosted cell killing efficiency in in vitro prostate cancer cells that overexpress Bcl-2 
(Song 2012). Another Pim-1 inhibitor, ETP-45299, was shown to act synergistically with a PI3K 
inhibitor, GDC-0914, in apoptosis induction and translation inhibition in AML cells. The study also 
demonstrated that Bad and 4E-BP1 phosphorylation were double-targeted by this combination 
strategy and lead to extensive cell killing (Blanco-Aparicio 2011). In addition, in multiple myeloma 
(MM), a Pim-2-specific inhibitor, (Z)-5-(4-propoxybenzylidene) thiazolidine-2,4-dione, and PI3K 
inhibitor, LY294002 cooperatively enhanced MM cell death levels (Asano 2011).   
Combinations of Pim kinase inhibitors with FDA-approved chemotherapeutic agents or 
other investigational agents have been reported to have greater effects compared to single agent 
therapies. A study in renal cell carcinoma (RCC), where c-Myc is overexpressed and known to drive 
tumorigenesis, addition of Pim kinase inhibitor, SGI-1776 enhanced the effect of sunitinib (an FDA-
approved receptor tyrosine kinase inhibitor for treating RCC) in reducing phospho- and total c-Myc 
levels as well as expression levels of c-Myc-regulated genes, in addition to promoting anticancer 
activities (Mahalingam 2011). Furthermore, another study in MM demonstrated that reduction of cell 
viability by mTOR inhibitor rapamycin was enhanced when Pim-2 expression was repressed by 
PIM2 siRNA due to a cooperative effort in repressing 4E-BP1-regulated translation processes 
(Asano 2011). Moreover, combination of Vorinostat, (suberoylanilide hydroxamic acid, SAHA‒an 
FDA-approved inhibitor of class I&II histone deacetylases for treating cutaneous T-cell lymphoma) 
with a Pim kinase inhibitor, ETP-39010 resulted in an additive to synergistic effect in multiple cell 
lines tested (Wozniak 2010). In addition, SGI-1776 single agent treatment was able to increase cell 
death levels in a multidrug resistance 1 protein (ABCB1)–based prostate cancer cell line that are 
refractory to taxane, a widely used chemotherapeutic agent for many cancers. SGI-1776 was also 
able to re-sensitize chemoresistant cells to taxane-base therapies by inhibiting ABCB1 expression 
(Mumenthaler 2009).  
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The examples described above provided strong rationale for the feasibility of Pim kinase 
inhibitors used in combination treatment, which could improve efficacy and decrease Pim kinase 
inhibitor-derived toxicity in clinic.  
Advantage of using Pim kinase inhibitor to prevent drug resistance 
  In addition to oncogenic pathways described above, all three Pim kinases are mediators for 
drug resistance development (Brault 2010). A common mechanism for drug resistance is through 
insufficient drug transportation into cancer cells, due to changes or overexpression of trans-
membrane transporter molecules, known as drug efflux pumps. Pim-1 is able to phosphorylate and 
activate the ATP-biding cassette (ABC) transporters p-glycoprotein (ABCB1) and breast cancer 
resistance protein (ABCG2), which are transporter molecules strongly associated with acquired drug 
resistance in cancers such as AML (Ji 2009; Natarajan 2013).  
By knocking down Pim-1 expression, ABCB1/ABCG2-mediated drug resistance was 
inhibited in AML cells overexpression ABCB1/ABCG2 (Natarajan 2013). In leukemia cells with 
high levels of Mcl-1 (another factor known to cause chemoresistance), increased the sensitivity to 
cytotoxic agents was made possible, by specifically targeting both Mcl-1 and ABCB1 (Ji 2009). 
These studies indicated that targeting Pim kinases along with one or more oncogenic pathways to 
which the tumor cells are addicted may be a desirable approach for treatment refractory cancer 
patients.  
IV. Conclusion and future directions 
The investigations described in this dissertation focuses on investigating Pim kinases as 
therapeutic targets and evaluating the effect of Pim kinase inhibitor, SGI-1776 in MCL, as well as 
combination approach of SGI-1776 with chemotherapeutic agent, bendamustine in B-cell lymphoma.  
We were able to identify that SGI-1776 is a cytotoxic agent in MCL, that targets c-Myc-driven 
transcription and cap-dependent translation processes to disrupt MCL survival. In addition, global 
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RNA and protein synthesis were disrupted, and short-lived oncogene MCL1 mRNA and its protein 
expression were decreased. Meanwhile, SGI-1776-induced cytotoxicity was not observed in normal 
PBMCs. In B-cell lymphoma cells, bendamustine was effective in disrupting DNA synthesis as well 
as inducing DNA-damage response, whereas SGI-1776 decreased RNA and protein syntheses. When 
used in combination, additive to synergistic effect in cell killing was observed, and more extensive 
decrease of macromolecule synthesis was detected in B-cell lymphoma cell line and primary cells.  
Our study in SGI-1776 provides a mechanism of action that may be used to guide future 
clinical trial studies of Pim kinase inhibitors, and the combination study with bendamustine supports 
the feasibility of using Pim kinase inhibitor with other chemotherapeutic agents. However, two 
questions remain unclear ‒whether other mechanism of apoptosis induction are involved in SGI-
1776-induced cell death, and if redundant pathways are activated when Pim kinases are repressed 
either by a small molecular inhibitor or siRNAs. To identify other mechanisms of SGI-1776-induced 
cytotoxicity, we may look outside of direct phosphorylation targets Pim kinase, and to look more 
closely into the intrinsic/extrinsic apoptosis-regulating pathways, and other members of Bcl-2 family, 
and examine the regulating molecule more closely. We will also conduct screening studies to look 
for upregulated oncogenes in PI3K, NF-ĸB, and Wnt pathways (all are known to be deregulated in 
MCL) in order to identify redundant pathways of Pim kinases (Perez-Galan 2011).     
Due to limited number of lymphoma primary patient cells, we were unable to examine the 
molecular mechanism of the combination treatment, and greater number of MCL cell lines and 
primary samples are needed to confirm our findings of macromolecule synthesis inhibition and 
identify the important players and oncogenic pathways affected by combination treatment.  
In addition, other Pim kinase inhibitors could be tested in B-cell lymphomas, to compare and 
validate the mechanisms of actions of SGI-1776. We hypothesize that pan Pim kinase inhibitors may 
have a greater effect in apoptosis induction in MCL cells, and the output of downstream 
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phosphorylation targets may be different for selective Pim-2 or Pim-3 inhibitors compared to SGI-
1776.  
Moreover, effect of SGI-1776 under microenvironment conditions is another important 
aspect of study to better understand the mechanism of actions of the drug in patient body. 
Microenvironments contain many growth factors and cytokines/chemokines are known to upregulate 
oncogenic pathways such as JAK/STAT or PI3K/Akt/mTOR to enhance oncogenecity and drug 
resistance of lymphoma cells (Chen 2010; Burger 2011). Importantly, Pim kinases are known to be 
regulated and interact with growth factors and cytokine/chemokines from microenvironment. 
Specifically, it was reported that Pim-2 is downstream of B lymphocyte stimulator (BLyS), and it 
acts independently from Akt/mTOR pathway to enhance B cell growth and survival (Woodland R.T. 
2008). In addition, expression of Mcl-1, a reporter protein downstream of BLyS was also increased 
in the presence of BLyS and activated BCR pathways (Woodland R.T. 2008). Moreover, Pim-1 was 
reported to regulate C-X-C chemokine receptor 4-12 (CXCR4-CXCR12)-mediated homing and 
migration processes in AML (Grundler 2009). Based on these evidences, it is reasonable to speculate 
that the effect of Pim kinase inhibitors such as SGI-1776 may be different under the influence of 
microenvironment compared to microenvironment-free conditions. 
Finally, effect of SGI-1776 and other Pim kinase inhibitors need to be investigated in mouse 
models to better understand the dose-efficacy relationship, and to predict potential toxicities in 
patients before they enter the clinic. Xenograph models are good systems to study the efficacies of 
Pim kinase inhibitors, as they readily reflect the drugs’ effect by easily-measured reduction of tumor 
volumes and prolonged survival in mice. However, xenograph models differ from human physiology 
by lacking immune systems, which may become important in study hematological malignancies. 
Additional in vivo models such as gene knockout mice may also be used to complement in vitro 
studies. Importantly, metabolites of each Pim kinase inhibitor needs to be analyzed and investigated 
to more accurately predict toxicity in the clinic.   
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